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This dissertation is a compilation of work on the development of new methods and 
models to study neurochemical changes. Using fast-scan cyclic voltammetry to measure 
electroactive species is the common theme that ties these projects together. This electrochemical 
technique is the method that we have chosen to either apply to a new animal model for sub-
second neurotransmitter release, zebrafish, or in conjunction with photochemistry. 
In the 1st chapter we discuss work that we have done to develop caged compounds for use 
in neurochemical experiments. We discuss work on the synthesis of caged thiols and phenols and 
how we have probed their photochemical mechanisms. We also discuss work we have done on 
developing a novel probe to measure electrochemical changes while simultaneously carrying out 
photochemical reactions. 
In the next two chapters we discuss work we have done in zebrafish studying sub-second 
dopamine release. We have shown that it is possible to measure dopamine release from both 
whole brain preparations ex vivo as well as sagittal and coronal slices. We discuss the 
pharmacology of this release as well as unique characteristics of the uptake plots. We also 
examine how different uptake inhibitors effect the kinetics of the dopamine uptake. 
Finally we discuss work we have done on the chemotherapy induced changes in zebrafish 
dopamine release. We look at 2 drugs, 5-FU and carboplatin, and two treatment pathways, 
habitat water and food. We show that there is a pathway dependent attenuation for both of the 
drugs studied that is not correlated with apparent changes in uptake. The food delivery pathway 
was found to have an effect on dopamine release on a much shorter time scale then the habitat 
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Chapter 1: Introduction 
1.1 Dopamine: Synthesis, release, and uptake 
 Dopamine is a monoamine neurotransmitter found in a wide range of vertebrate species 
including fish, rodents and humans. This neurotransmitter is involved in many neurological 
processes which include memory and learning 1, reward and addiction2, 3, and movement4, 5. 
Deficiencies in dopamine neurotransmission have also been observed in many neurological 
conditions, such as Huntington’s Diesease6-9, Parkinson’s Disease10, 11 , Alzheimer’s Disease12, 13 
, multiple sclerosis14, and Chemotherapy induced cognitive impairment15.  
 
 
Figure 1: Major dopamine pathways in the adult mouse brain. The Nigrostriatal pathway is green 
and the mesolimbic and mesocortical pathways are blue. Reproduced with permission from 
Frontiers in neuroscience 16 
 
 In mammals, the dopaminergic system has major projections that extend from the ventral 
tegmental and the substantia nigra to the neostriatum, limbic cortex and other limbic structures.17, 
18  The first projection listed is termed the nigrostriatal system and controls movement19 (Figure 
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1). These last two projections are termed the mesocortical and mesolimbic systems respectively, 
and have been implicated in learning, reward and addiction20, 21(Figure 1).  
Figure 1: Dopamine synthesis in neurons. 
 Dopamine is synthesized intracellularly from tyrosine in the pathway shown in Figure 2. 
The rate-determining step of the entire process is the conversion of tyrosine to L-DOPA by 
tyrosine hydroxylase. L-DOPA can then be converted to dopamine by DOPA decarboxylase. 
Once dopamine is synthesized, it is packaged in vesicles within the neuron by the vesicular 
monoamine transporter 2 (VMAT2) 17, a membrane-bound protein that utilizes a proton gradient 
to transport monoamines into the vesicles.22  When an action potential occurs, these vesicles 
merge with the cell membrane and dopamine is released into the synapse by a process called 
exocytosis. Dopamine released into the synapse can: 1) be taken up by presynaptic dopamine 
transporters (DAT), 2) bind to post- or pre-synaptic receptors, or 3) diffuse out of the synapse. 
 Depending on its location in the brain, dopamine can be metabolized by monoamine 
oxidase to DOPAC or by catechol-O-methyl-transferase (COMT) to 2-methoxytyramine23 
(Figure 3). Both of these products are then converted into homovanillic acid by COMT and 
MAO, respectively. In rodents and primates, DOPAC and HVA are the two most common 




Figure 3: Scheme showing the metabolism of dopamine. Dopamine can be consumed through 2 
pathways to be converted into either DOPAC or 3-MT. Both of these compounds would then be 
converted into HVA. 
 
1.2 Dopamine receptors 
 Dopamine receptors, which are found both postsynaptically and presynaptcally, are G-
protein coupled receptors that activate or inhibit neuronal function by either upregulating or 
downregulating adenylyl cyclase, respectively24. They are organized into two main classes, D1-
like and D2-like. The D1-like class includes D1 and D5 receptors and activate adenylyl cyclase, 
while D2-like receptors include D2, D3 and D4 receptors and inhibit adenylyl cyclase. All types of 
dopamine receptors are transmembrane receptors that have 7 hydrophobic transmembrane 
domains24.  
 We are primarily interested in presynaptic D2 receptors because they are the dopamine 
autoreceptors17. As mentioned above, an action potential can cause a neuron to release dopamine 
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and that dopamine can either be reuptaken or interact with post or presynaptic receptors. The D2 
autoreceptors  are a special class of presynaptic receptors in that when dopamine interacts with 
them dopamine released is stopped directly by the activation of potassium channels to depolarize 
the neuron or stopped indirectely by modulating tyrosine hydroxylase and DAT17, 25. Drugs that 
manipulate D2 autoreceptor activation are useful because they modulate the amount of dopamine 
released: antagonists such as sulpiride26, raclopride27, and eticlopride28 enhance the dopamine 
signal while agonists such as quinpirole29 suppress the signal. 
1.3 Voltammetry history and theory 
 The field of voltammetry was started in 1922 with the development of polarography by 
Jarsolav Heyrovsky. These early methods took hours and only had the ability to take 
measurements from a linear sweep of voltage. In 1942 Archie Hickling developed the first 3 
electrode potentiostat30, which facilitated measurements obtained by CV and linear sweep 
voltammetry by allowing a counter electrode to be added to the system. The modern 
electrochemical cell used in voltammetry experiments has 3 electrodes: the working electrode,  
the reference electrode, and the counter electrode (Figure 4). For a given measurement cycle, a 
potential is applied to the working electrode, moving from a holding potential to a switching 
potential and back to a holding potential over a time scale that is dependent on the scan rate of 
the experiment. As that potential changes, electroactive species can be oxidized or reduced. This 
electrochemical process leads to a faradaic current that can be measured. By plotting the current 
observed vs the potential applied chemical information can be ascertained. These plots are called 





Figure 4: A diagram of a 3-electrode system, The potentiostat is able to isolate the current from 
from the reference electrode by passing it through the counter electrode.  
 
 The potential at a working electrode is obtained by comparison with a reference electrode 
31 In reality, a system only needs two electrodes to make measurements, a working electrode and 
a reference electrode. However, in a 2-electrode setup, the reference electrode is coupled directly 
with the working electrode to carry out the faradaic reaction. This system makes accurate control 
of applied potential impractical due to IR drop, a phenomenon in which the potential decreases 
as current increases, according to Ohm’s law (E = IR)32. In order to mitigate this problem, a 
mostly inert electrode, known as the counter electrode, is introduced into the system. In the three 
electrode system, this electrode completes the circuit so current can pass, thereby keeping the 
reference electrode potential constant. 
 The reactions our group studies can be described by the Nernst equation (Equation 1) 
because they are reversible (a reaction where the reduction and oxidation potential are separated 
by less than 0.058 Volts/n)31. This equation describes how the concentration of oxidized and 


















formal reduction potential of the analyte, R is the universal gas constant, n is the number of 
electrons per reaction, and F is the faraday constant.31 







 The peak current for a reversible reaction can be described by the Randles-Sevcik 
equation (Equation 2)31.  








In this equation, ip is the peak oxidation current, n is the number of electrons transferred in the 
reaction, A is the electrode area (cm2), D is the diffusion coefficient for the molecule of interest 
(cm2/s), C is the concentration of the species oxidized (mol/cm3) and ν is the scan rate (V/s). This 
equation describes a relationship in which the concentration of the species oxidized is directly 
related to the scan rate, area of the electrode, and the current measured at the electrode. This 
means that, as long as the electrode area and scan rate are held constant, the concentration and 
faradaic current are directly related and can be interconverted. This interconversion allows the 
measurement of concentrations of electroactive species. 
 
1.4 Electrochemical measurement of neurotransmitters with fast-scan cyclic voltammetry 
(FSCV) 
 The electrochemical measurement of neurotransmitters in brain tissue was first published 
in 1973 by Ralph N Adams and coworkers, who used carbon paste electrodes to measure 
ascorbic acid by CV 33. In the early 1980s, independent work by Wightman34 and Millar35 
resulted in the development of fast-scan cyclic voltammetry (FSCV) at carbon-fiber 
microelectrodes36, 37. In brief, FSCV is a technique in which a triangular potential waveform (-
0.4 V to +1.3 V to -0.4 V as used in our laboratory for the detection of dopamine) is applied at a 
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high scan rate (>100 V/s) 38, 39.  The carbon-fiber microelectrodes used in our laboratory have a 
diameter of 7 µm and are trimmed to ~50 µm in length (Figure 5).  
 FSCV has several advantages that make it suitable for neurobiological applications: 1) 
the small electrode size provides high spatial resolution, thereby allowing specific brain 
structures to be selected; 2) carbon is biologically inert; 3) the diffusional properties and 
microelectrodes allow steady state (or quasi steady state) currents to be quickly attained, thereby 
allowing high temporal resolution measurements;  and 4) the small currents measured allow CV 
measurements to be obtained using a 2-electrode system in highly resistive environments, such 
as brain tissue40, 41. Because the high scan rate generates a large, non-faradaic current, which 
results from charging of the electric double layer, a background subtraction process is required to 
reliably identify the faradaic currents produced by the chemical species of interest, such as 
dopamine. This background subtraction method is illustrated in Figure 6. For a given 
measurement, a series of CVs is collected at a predetermined application frequency (typically 10 
CVs/s) for a pre-determined period of time (typically on the order of 20 s). The average current 
of 10 CVs obtained when dopamine is not present (we are neglecting basal dopamine levels in 
this case) is subtracted from the CVs obtained throughout the entire data set. Because the 
background current at a given scan rate is quite stable, subtraction of this current removes this 
current and, ideally, leaves all other signals of interest42.  Because the remaining faradaic signal 
is directly dependent upon concentration, each electrode can be calibrated in a flow cell against 




Figure 5: An SEM image of a carbon fiber microelectrode. This image was obtained at KU 








Figure 6: An illustration of the background subtraction process. (A) is the signal from dopamine 
plus the charging current, (B) is the background current alone taken from scans before the 
dopamine signal was introduced. (C) Is the signal after B is subtracted from A leaving just the 
dopamine signal with the indicative dopamine CV. 
 
1.5 Electrochemical measurement of dopamine with FSCV 
 The compound of interest throughout this work, as mentioned above, is dopamine and 
here its electrochemistry will be briefly discussed. Dopamine is a monamine that can be oxidized 
at 0.6 V at a carbon-fiber microelectrode (versus a Ag/AgCl electrode) to dopamine 
orthoquinone, which can then be reduced back to dopamine at -0.2 V (Figure 7) in a reversible 




Background + DA Signal  




signal. This faradaic oxidation current can then be used to determine the concentration of 
dopamine, because of the Randles-Sevcik discussed above, by calibration against standard 
dopamine solutions. In our work, a waveform of -0.4 V to 1.3 V to -0.4 V at 400 V/s, applied 
every 100 ms, is used to measure dopamine. We selected a switching potential of 1.3 V instead 
of the standard switching potential of 1.0 V to enhance adsorption of dopamine to the electrode, 
making it more sensitive.43 This increase in absorption is caused by an increase in ester and 
carboxylic acid groups on the carbon surface which can interact with the amine group on 
dopamine.44, 45 
 
Figure 7: Fast-scan cyclic voltammetry of dopamine. A waveform of -0.4 to 1.3 V and back to -
0.4 V at 400 V/s is applied once every ten seconds. As the voltage is scanned toward the positive 
potential, dopamine is oxidized to dopamine-o-quinone. As the potential is scanned back to the 
negative potential, dopamine-o-quinone is reduced to form dopamine. After background 






1.6 Zebrafish as model organisms for neurochemical analysis 
 The use of model organisms is essential to simulate the complex environment of the 
human brain. Model organisms used range from simple invertebrates such as fruit flies46, 47 to 
complex mammalian systems such as mice, rats, and primates48, 49. FSCV at carbon fiber 
microelectrodes in rodents has been used extensively to study dopamine both in vitro6, 15, 50, 51 
and in vivo52-55.  Rodents have been used to increase our basic understanding of how 
neurotransmitter release relates to behavior50, 51, 54 as well as disorders and diseases including 
addiction52, 53, neurodegeneration6, 55 , Huntington’s Disease6, Parkinson’s Disease55 and 
Chemotherapy induced cognitive impariment15.  
 While rodents are useful model organsims, there are disadvantages to using them 1) the 
creation of genetically altered mammals is costly and time-consuming; 2) treating rats or mice 
using injection methods are both difficult and stressful on both the animal and the experimenter. 
 One of the main goals of our group recently has been the development of zebrafish as a 
new model for neurochemical studies. Zebrafish, first developed by George Streisinger in the 
1970s 56 as a model for development57, also are a useful model organism for the study of 
neuronal function because they: 
1. are a vertebrate, unlike fruit flies or C. elegans, and, therefore, have greater 
anatomical similarity to humans.  
2. have a completely sequenced genome that has ~ 70% similarity to the human 
genome.58 
3. can be easily housed in large numbers cheaply and have a short life cycle with a 
large amount of offspring. 
4. can be genetically modified easily unlike rodents59  
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5. possess complex brains of ideal size that can be kept alive in a perfusion chamber 
away from the body60, unlike rodents. 
6. are easy to treat with pharmacological agents, which often can be given to them 
by simply adding it to their water habitat61, 62 as well as food63. 
7. they react to pharmacological agents similarly to how rodents react.64   
 
1.6.1 Zebrafish vs rodent neuroanatomy 
 Extensive staining studies have been used to elucidate the zebrafish’s neuroanatomy. 
These studies have shown that dopamine, norepinephrine, histamine, and serotonin are all 
present in the zebrafish central nervous system65. The catecholamine system, and more 
specifically the dopamine system, retains many of the same proteins. Zebrafish and rodents both 
have tyrosine hydroxylase (although zebrafish have 2 distinct versions of the protein66), MAO 
(although zebrafish only have one version of MAO)65, 67, 68, COMT, and all of the families of 
dopamine receptors (though zebrafish have 8 whereas rodents have 5)65. The dopaminergic 
system in zebrafish has been studied using histology. It has been shown that one of the main 
projections is an ascending system from the diecephelon to the ventral telecephelon 69, 70. Based 
on staining studies, it is thought that this system is similar to the mesolimbic system in rodents. 
 Rink and Wulliman71 used histochemical staining against tyrosine hydroxylase to show 
that there were dopaminergic neurons present in the fore brain. These neurons were mainly 
found in the diencephalon and the telencephalon with projections running from the former to the 
later. They also noted that because of the evolutionary history of dopaminergic pathways there is 
a possibility that these neurons are similar to the mesolimbic system in mammals, even though 
these neurons are not found in the midbrain.  
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 The neuroanatomy of zebrafish has also been studied after application of known 
neurotoxins with well documented effects in rodents. After larval zebrafish were treated with 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)  and 1-methyl-4-phenylpyridinium (MPP+), 
Panula et al72 observed a decreases in tyrosine hydroxylase labeled neurons in the diencephalon. 
This loss of neurons was associated with decrease in swimming speed. There was also a 
decreased in total dopamine content as measured by HPLC. Similar loss of diencephalic 
dopamine neurons and decrease in movement after MPTP treatment have also been reported by 
Lam et al.73 and Bretaud et al. 74 Since there was a decrease in movement coupled with the 
neuronal death in these studies it has been proposed that part of the diencephalon is similar to the 
rodent substantia nigra. 
1.7 Previous studies in Zebrafish  
 Neurotransmitter levels in zebrafish have been previously measured directly by both real 
time electrochemical measurements as well as by HPLC methods. Zebrafish neurotransmission 
has also been studied using electrophysiological methods. This section will briefly review these 
studies, with an emphasis on studies drawing comparisons between zebrafish and mammals in 
order to try to make the argument that zebrafish are a viable model to study disorders that effect 
humans. 
1.7.1 HPLC measurements in zebrafish 
 Robert Gerlai’s group has used HPLC coupled to electrochemical detection to measure 
the amount of dopamine and serotonin as well their metabolites DOPAC and 5-HIAA. These 
measurements were conducted both post and pretreatment with alcohol75, 76.  Gerlai and 
coworkers showed that as the adult fish were treated with increasing amounts of ethanol the 
amount of all the compounds studied increased.75 They also showed that when the embryos were 
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treated with ethanol the amount of the compounds studied decreased. 76 His group has also 
showed that the strain of fish effects how the attenuation of neurotransmitter content after 
treatment of the embryo with alcohol presents itself, with some strains mitigating the effects77.  
 Panula and coworkers showed dopamine content was attenuated after adult fish were 
injected with the catecholaminergic toxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyrdine (MPTP).78 72The amount of dopamine was reduced to about 40 
% of the saline value after 1 week of MPTP treatment and to 59% of control values after 6-
OHDA treatment.78 They also showed that the zebrafish locomotion was decreased for both 
treatments, something that would also be expected for rodents treated with these same drugs.  
 I have selected these two specific examples to illustrate how zebrafish have been used to 
study important process such as fetal alcohol syndrome and neurodegeneration. Zebrafish have 
also been studied with HPLC methods to study cocaine withdrawal 79 , stress 80, and the 
maturation of zebrafish behavior81.  
1.7.2 Electrophysiological measurements in zebrafish 
 Electrophysiology has been applied to zebrafish in order to study the neuronal firing 
associated and correlate it with observed behavioral effects. Work has been done by Baier and 
coworkers showing that zebrafish react to pentylenetetrazole similarly to what is observed in 
rodents with a large increase in movement that is correlated with an increase in seizure like 
neuronal firing in the optic tectum82. They also showed that anticonvulsant agents (valproic acid 
and diazepam) reduced the amount of seizure like neuron firing, just as would be expected in 
mammals.  
 Douglass et al studied induced escape behavior in zebrafish and correlated the behavior 
with electrophysiology studies to try to elucidate what neuronal families were firing83. In order to 
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do these studies they expressed channelrhodopsin-2 in neurons that are known to be involved in 
these escape movements. They then showed, in larvae zebrafish, that there was no basal firing of 
these modified cells, that there was firing of the cells when light was introduced and that this 
firing was related to the observed escape behavior. Electrophisology has also been used to study 
photochemically induced neuron silencing84, Dravet syndrome85, 86 and Mauthner cells87. While 
electrophysiology can be used to determine when cells are firing it can’t provide specific 
information about neurotransmitter release like FSCV is able to. 
1.7.3 Real time release measurement in zebrafish 
  To the best of our knowledge, two other groups have made real time measurements of 
neurotransmitter release in zebrafish. Jones et al. made evoked neurotransmitter release 
measurements in sagittal zebrafish slices88 with FSCV after the application of both chemical and 
electrical stimulation from the brain slice. They demonstrated that dopamine was one of the 
components of a mixture that included pH change and histamine. This was determined by using 
GBR 12909 and cocaine to pharmacologically manipulate the dopamine portion of the signal as 
well as by using principal component analysis to isolate the dopamine signal from the other 
components. They determined that the [DA]max was about 100 nM after stimulation.  
 Shang et al were able to measure real time dopamine release using amperometry in larval 
zebrafish after scent stimulatoin89. They showed that the signal observed was dopamine using 
pharmacological manipulations and staining studies. They applied nomifensine and observed 
both an increase in the signal as well as a decline in uptake. They also used calcium imaging in 




 As can be seen by the brief review of current work done in the zebrafish brain, it is 
already a model that has been shown to be able to model disease states such as alcoholism and 
epilepsy as well as neurodegeneration. It is also clear that real time measurements are possible 
using electrochemistry, as has been demonstrated in both adult brain slices and larvae. In this 
dissertation we discuss work that expands on this previous work by moving into real time 
measurements in whole intact adult zebrafish brains ex vivo60 as well as work we have done to 
expand zebrafish as a model of chemotherapy induced cognitive impairment. 
1.8 Outline of chapters 
 Chapter 2 discusses work I have done towards the development and application of 
photochemical probes to study biological systems. It includes work we have done with both 
phenol and thiol moieties and our attempts to develop new and biologically relevant molecules 
that contain those previously mentioned moieites. I also discuss work that has been done towards 
the development of a device to simultaneously apply, uncage and measure these compounds in 
tissue samples. 
 Chapter 3 discusses the initial development of methods to measure dopamine from 
zebrafish whole brains ex vivo done by Mimi Shin. It also discusses how the identity of the 
released neurotransmitter was determined and examines the pharmacology of that signal. Finally, 
unique characteristics of the release and uptake curves in zebrafish are examined and explained.  
 Chapter 4 discusses work that has been done examining the effects of chemotherapy 
treatment, specifically 5-FU and carboplatin, on the neurochemistry of the zebrafish brain.  
Comparisons are also drawn between this work and the work done by Sam Kaplan and Rachel 
Ginther in order to demonstrate that the phenomena observed in the zebrafish is similar to what 
is observed in rodents.  
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 Concluding remarks are provided in Chapter 5. 
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Chapter 2: Development of photochemical methods for the study of 
neurochemical processes 
Abstract 
 In this chapter we discuss the synthesis of model compounds to examine the 
photochemistry of p-hydroxyphenacyl (pHP) protected thiols and phenols. We were able to 
successfully synthesize a model phenol, pHP-p-cyanophenol, that was shown to cleanly undergo 
deprotection chemistry via the photo-favorskii rearrangement. A pHP protected thiol was also 
synthesized and was shown to likely undergo an uncaging mechanism involving homolytic 
cleavage via a radical mechanism. Finally, an optrode that can detect dopamine in both a flow 
cell and brain slice, as well as direct light to tissue in the vicinity of the electrode, will be 
discussed.  
2.1 Introduction 
 Caged compounds are molecules that have been chemically protected by a group that can 
be photochemically removed (an uncaging reaction scheme for the pHP group is shown in Figure 
1) 1, 2. When the uncaging occurs, the protected compound is released (red) and a byproduct of 
the cage is produced (blue). This photochemical reactivity has led to a great deal of interest in 
using these compounds for biological applications because of the ability to deprotect the 
compound of interest in a spatial and temporally resolved way without the introduction of harsh 
external chemicals to the sample. These properties are highly relevant in biological studies 
because of the high level of spatial heterogeneity that can be observed in these living systems.  
The ideal caged compound for biological studies should satisfy four important criteria: 1) 
The compound must be rendered biologically inert by the introduction of the photoprotecting 
group. 2) The compound of interest must be released in high yield while limiting other undesired 
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products. 3) The group must undergo photolysis with light that does not have sufficient energy to 
damage the tissue of interest. 4) The byproduct of the photorelease must be biologically inert and 
not interfere with the photochemical reaction of uncaging 1-3.  
 
Figure 1: An example uncaging reaction using the p-hydroxyphenacyl (pHP) protecting group. 
The photoprotecting group in blue on the reactants side is chemically bonded to the leaving 
group of interest in red. When light (hν) is applied, a photochemical reaction takes place that 
releases the leaving group in red and produces a byproduct of the caging group in blue on the 
products side.  
 
2.1.1 Photoprotecting groups 
 Many photoremovable groups have been used in the field of biological research4, 
including o-nitorbenzyl5, 6, benzoins7, 8,and coumaryl groups9. The o-nitrobenyl group is one of 
the most extensively used groups3 because of its ease of synthesis and high levels of 
compatibility with functional groups of biological interest. While it is the most common, it does 
not satisfy all 4 of the requirements outlined above, since the byproduct of the photochemical 
reaction, 2-nitrosobenzaldehyde, is toxic to biological systems10. Therefore it has been necessary 
for researchers to look for alternative protecting groups that can be used in biological systems. 
One such protecting group, and the one that will be studied in this chapter, is pHP (Figure 1). 
 The pHP protecting group was developed by Richard Givens at the University of Kansas 
in 1996 11, 12 and has many attributes that make it an attractive alternative to o-nitrobenzyl. The 


















compound that has a absorption blue shifted away from the parent caged compounds 11 . The 
pHP protecting group has also been shown to have high quantum yields, rapid rates of 
photorelease, and high aqueous solubility 13. This protecting group undergoes a photo-favorskii 
type rearrangement mechanism, shown in Scheme 1, when the reaction is carried out in solvents 
containing an aqueous component 14, 15. All of these factors taken together make pHP a 
promising group for our chemistry. 
 
Scheme 1: Photo-favorskii rearrangement of a pHP caged compound 
 The pHP protecting group has been used successfully with leaving groups that are 
conjugates of strong acids (amino acids11, phosphates16, carboxylates17), however, there has been 
limited success with phenolate based leaving groups18. Phenols are an important moiety found in 
D2 receptor antagonists, such as eticlopride and raclopride. In this work we hoped to expand the 
application of pHP to phenolate containing compounds in order to modulate these antagonists’ 
chemistry. Another group that we have become interested in are thiols, which are important in 
glutathione peroxidase chemistry. One of the main goals of this chapter is to show our work in 
the development of phenol and thiol based pHP compounds with the eventual goal of protecting 
compounds that are relevant to neurochemical studies. Additionally, we show progress made on 
developing a probe that can be used in vivo to photorelease caged compounds while measuring 
sub-second neurotransmitter release.  
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2.1.2 Electrochemical tracking of photochemical reactions 
 As was mentioned above the byproduct of the photo-favorskii rearrangment of pHP, 4-
HPAA, is electrochemically active19. This property allows for the electrochemical quantification 
and tracking of the photochemical release of non-electrochemically active compounds. Our lab 
has shown this using a pHP protected glutamate. We have also shown that it is possible to 
measure the uncaging of pHP protected glutamate and the electrically stimulated release of in 








Figure 2: (A) In a brain slice the working electrode is placed in between the biphasic stimulating 
electrode. A 200 µm fiber optic is placed over the working electrode. (B) The cyclic 
voltammogram taken at the dotted line is in panel C. It shows characteristics of dopamine with 
an oxidation peak at 0.6 V  and of 4-HPAA with an oxidation peak at 1.3 V. (C) The color plot 
for a recording. The signal at 3 seconds represents the light artifact and 4-hpaa oxidation at 3 
seconds when light is introduced. The signal at 5 seconds where the dotted white lines cross is 
the electrically stimulated dopamine release. (D) The current vs time plot showing the light 
artifact at 3 seconds and the dopamine signal at 5 seconds. 
 
  One of the main difficulties our lab has discovered when attempting to do these 
experiments is the difficulty in aligning the fiber optic light guide with the working electrode and 
the difficulty in minimizing the amount of valuable caged compound that needs to be used in 
these experiments. In order to try to overcome these difficulties our group has also worked on 
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capillary for the injection of the compounds of interest. The reminder of this chapter will be a 
discussion of our work in trying to develop novel caged compounds and optrode technology. 
2.2 Methods 
2.2.1 2-bromo-1-(4-hydroxyphenyl)ethan-1-one 
  A 100mL round bottom flask was charged with 1g p-hydroxyacetophenone (7.35mmol) 
and 3.6g CuBr2 (16.2mmol) and 1:1 CHCl3: ethyl acetate (v:v). This mixture was stirred under 
reflux for 6 hours or until the solution turned from green to red. This solution was run through a 
silica plug yielding an amber liquid. Solvent was removed under vacuum. The product was 
purified by recrystallization in toluene giving a purple crystal. H1 NMR 400mHz (CDCl3) δ 
4.41(2H, s), δ 6.92(2H, d), δ 7.95(2H, d).  
2.2.2 4-(2-(4-hydroxyphenyl)-2-oxoethoxy)benzonitrile  
 A 100 mL round bottom flask was charged with 0.352 K2CO3 and 0.303g 4-cyanophenol 
in THF and was stirred at 4 C. To this mixture a solution of 0.5 g  2-bromo-1-(4-
hydroxyphenyl)ethan-1-one in THF was added dropwise over 1 hour. After this addition, the 
reacting mixture was allowed to return to rt and stirred for an additional 24 hours. The solvent 
was removed under vacuum to yield a crude solid. The product was purified via flash 
chromatography with 3:1 hexanes: ethyl acetate. Product was a fine white powder. Yield-23%. 
H1 NMR 400mHz (CD3CN) δ 5.48(2H, s) δ 6.95(2H, d) δ 7.05(2H, d) δ 7.67(2H, d) δ 7.92(2H, 
d). HRMS, M-H, 252.0661, found, 252.0655.  
2.2.3 1-(4-(Benzyloxy)phenyl)ethan-1-one:  
 A 250 ml round bottom was charged with 1.01 g (7.42 mmol) of p-hydroxyacetophenone, 
3.00 g (21.7 mmol) of K2CO3, and acetonitrile. This solution was stirred at rt while 0.880 ml 
(7.35 mmol) of benzyl bromide was added dropwise and the final solution was stirred for 20 
36 
 
hours. The solvent was removed under vacuum and the resulting white residue was dissolved in 
1:1 H2O:ethyl acetate (v:v) and extracted with 30 ml 1 M NaOH 4 times. The combined organics 
was dried with MgSO4 and the solvent was removed with reduced pressure giving a white solid. 
White solid (1.36 g, 82%), H1NMR (400 MHz, CDCl3) δ 2.56 (s, 3H), 5.14 (s, 2H), 7.01 (d, J = 8 
Hz, 2H), 7.42 (m, 5H), 7.94 (d, J = 8 Hz, 2H). 
2.2.4 2-Bromo-1-(4-phenoxyphenyl)ethan-1-one:  
 A 250 ml round bottom was charged with 513.7 mg (2.27 mmol) of 1-(4-(4-
methoxyphenoxy)phenyl)ethan-1-one and 1085 mg (4.86 mmol) of copper(II) bromide in 30 ml 
of 1:1 CHCl3: ethyl acetate (v:v). The solution was brought to reflux, turning brown then green, 
and run until completion was determined by TLC (4-6 hours). The green solution was filtered 
through a silica plug and the solvent was removed under vacuum resulting in brown oil. This oil 
was recrystallized in absolute ethanol and 2-bromo-1-(4-phenoxyphenyl)ethan-1-one, a 
brown/tan solid, was collected via vacuum filtration. Tan solid (330.2 mg 47.7%), H1 NMR (400 
MHz, CDCl3) δ 4.41 (s, 2H), 5.16 (s, 2H), 7.05 (d, J = 12 Hz, 2H), 7.43 (m, 5H), 7.98 (d, J= 
8Hz,2H)    
2.2.5 Methyl 5-chloro-2-(2-oxo-2-(4-phenoxyphenyl)ethoxy)benzoate:  
 A 50 ml round bottom was charged with 37.3 mg (0.12 mmol) of 2-bromo-1-(4-
phenoxyphenyl)ethan-1-one , 49.06 mg (0.355 mmol) of K2CO3 and 48.8 mg (0.262 mmol) of 
methyl-5-chlorosalicylate dissolved in 30 ml acetonitrile. The resulting solution was stirred at rt 
and run until completion was determined by TLC. The solvent was removed under vacuum and 
the resulting red-brown residue was dissolved in 1:1 H2O: ethyl acetate (v:v) and extracted 3x 
with 20 ml 1 M NaOH. The solution was filtered and solvent removed under vacuum to a crude 
yellow-red solid. The solid was purified with flash chromatography (ethyl acetate: n-hexane 1:4, 
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v:v). Yield: 14.8 mg, 29.5%. H1 NMR (400 MHz, CDCl3) δ 3.88 (s, 3H), 5.15 (s, 2H), 5.30 (s, 
2H), 6.84 (d, J = 8 Hz, 1H), 7.04 (d, J=8 Hz, 2H), 7.41 (m, 5H), 7.80 (d, J= 4Hz, 1H), 8.02 (d, J= 
8 Hz, 2H) 
2.2.6 1-(4-((4-Nitrobenzyl)oxy)phenyl)ethan-1-one:  
 An oven dried 100 ml round bottom was charged with 1.54 g (11.1 mmol) of K2CO3 , 640 
mg of 4-nitrobenzyl chloride and 495 mg of p-hydroxyacetophenone in acetonitrile. This 
solution was stirred for 4 hours at reflux turning a cloudy white then a tan brown. The solvent 
was removed under vacuum and the brown solid was dissolved in 1:1 water:ethyl acetate (v:v). 
The organic layer was extracted three times with 30 ml 1 M NaOH and dried over MgSO4. The 
solvent was removed under vacuum resulting in a red crude. This solid was recrystallized in hot 
ethanol and a tan solid was collected via vacuum filtration. Tan solid ( 697 mg 69.3%).  H1NMR 
(400 MHz, CDCl3) δ 2.59 (s, 3H), 5.27 (s, 2H), 7.03 (d, J = 8 Hz, 2H), 7.64 (d, J = 8 Hz, 2H), 
7.98 (d, J = 8 Hz, 2H), 8.29 (d, J = 8 Hz, 2H). 
2.2.7 1-(4-(4-Methoxyphenoxy)phenyl)ethan-1-one:  
 A oven dried 100 ml round bottom was charged with 212.3 mg (1.56 mmol) of p-
hydroxyacetophenone , 612.4 mg (4.43 mmol) of K2CO3 and acetonitrile. The resulting solution 
was stirred at rt while 0.203 ml (1.47 mmol) of 4-methoxybenzyl chloride was added dropwise, 
this solution was then stirred for 18 hours. The solvent was removed under reduced pressure and 
the residue was dissolved in 1:1 H2O: ethyl acetate (v:v).  This solution was extracted 3x with 
30ml of 1 M NaOH and the combined organic layers were dried over MgSO4. The solvent was 
removed under reduced pressure to give 1-(4-(4-methoxyphenoxy)phenyl)ethan-1-one as a 
white, crude solid. The solid was purified recrystallized in hot ethanol giving a white crystalline 
solid. White solid (330 mg 17%), H1 NMR (400 MHz, CDCl3) δ 2.57(s, 3H), 3.83 (s, 3H), 5.06 
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(s, 2H), 6.94 (d, J = 8Hz, 2H), 7.01 (d, J= 8Hz, 2H), 7.37 (d, J = 8 Hz, 2H), 7.94 (d, J= 12 Hz, 
2H). 
2.2.8 4-(2-bromoacetyl)phenyl acetate:  
 An oven dried round bottom was charged with 1.01 g of 2-bromo-1-(4-
hydroxyphenyl)ethan-1-one and 900 ml of triethyl amine in anhydrous diethyl ether. This 
solution was stirred under N2 ice while 0.428 ml of acetyl chloride (6 mmol) was added over a 15 
minute period. The resulting solution was stirred at room temperature for 4 hours turning white 
and cloudy. After 4 hours he solution was washed twice with 10 ml of water, 5% soda ash and 
saturated sodium chloride then dried of magnesium sulfate. The organic layer was rotovapped 
down to a tan solid. Tan solid (1.0 g 83 %) H1 NMR (400 MHz, CDCl3) δ 2.36 (s, 3H), 4.45 (s, 2 
H), 7.26 (m, 2H), 8.06 (d, 2 H, J = 8). 
2.2.9 Dimethyl-2-mercaptosuccinate:  
 An oven dried round bottom was charged with 3.01 grams of (14 mmol) of 
mercaptosuccinic acid 0.14 of H2SO4 (1.39 mmol) in methanol. This mixture as stirred for 4 
hours after which water was added to quench the reaction. This water methanol mixture was 
extracted with ether. The ether layer was then washed with 5% soda ash and dried with MgSO4, 
the solvent was then removed via vacuum leaving a clear oil (1.84 g, 47%) H1 NMR (400 MHz, 
CDCl3) δ 2.23(d, J = 4, 1H), 2.77 (dd, J = 8, 24, 1H), 3.02 (dd, J = 8, 24, 1H), 3.70 (s, 3H), 3.77 
(s, 3H) 
2.2.10 Dimethyl 2-((2-(4-hydroxyphenyl)-2-oxoethyl)thio)succinate: (Compound 4)  
 An oven dried round bottom was charged with 1.00 g (3.5 mmol) of dimethyl 2-((2-(4-
hydroxyphenyl)-2-oxoethyl)thio)succinate, 585 mg of K2CO3 (4.24 mmol) and 759 mg of pHP 
Br (3.53 mmol) in acetonitrile. This was stirred for 5 hours at room temperature, the solvent was 
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removed via vacuum leaving a crude solid. The solid was dissolved in ethyl acetate and extracted 
with water. The organic was then washed with 5% soda ash and the solvent was removed via 
vacumn to a ten solid. (yield 751 mg, 41 %) H1 NMR (400 MHz, CDCl3) δ 2.23(d, J = 4, 1H), 
2.79 (dd, J = 4, 20, 1H), 3.03 (dd, J = 8, 24, 1H), 3.70 (s, 3H), 3.75 (s, 3H), 5.77 (s, 2H), 6.91 (d, 
J = 8, 2H), 7.92 (d, J = 8, 2H) 
2.2.11 General Photolysis Procedure-UV analysis:  
 5mg 2,4-cyanophenoxy-4-hydroxyacetophenone was dissolved in 5mL 20% aqueous 
acetonitrile, buffered at pH 7.4 with a phosphate buffer. Solution was transferred to pyrex test 
tube. Samples were irradiated with Rayonet reactor under 8 300nm white lamps.  Samples for 
UV analysis were prepared by removing 50μL aliquots of irradiated sample with calibrated 
micropipette and diluted to 2mL in a volumetric flask. UV spectrum were taken after every 3 
minutes of irradiation.  
2.2.12 General Photolysis Procedure- NMR analysis  
 1mL of 3.5 x 10-3 M solution in 20% D2O D3-Acetonitrile was prepared and placed in a 
pyrex test tube for photolysis. A 0.6mL aliquot was removed in order to take an NMR spectrum 
after which it was returned to the test tube for further irradiation. 
2.2.13 General Photolysis Procedure-Mass spectrometry analysis 
  A 2mM solution of Compound 4 were prepared 5 mL 10% aqueous acetonitrile. Samples 
were irradiated with a Rayonet reactor under 8 300 nm white lamps for 10 minutes. Samples 
were analyzed using a eluent mixture of acetonitrile and water and a gradient of a 15 minute 
ramp from 95% organic, 5 % aqueous to 65 % organic, 35 % aqueous, 5 minutes to 1:1 organic 
aqueous, 1 minute to 5 % organic, 95 % aqueous, 1 minute to 95 % organic, 5 % aqueous 
followed by a hold at the same ratio for 4 additional minutes. The flow rate was held at 1.5 mL 
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throughout and the separation was conducted on a 15 cm C18 Ascentis column. Mass 
spectrometry analysis was conducted using a electrospray ionization source in negative mode 
coupled to a triple quadrupole detector.    
2.2.14 Actinometer  
 0.006M ferrioxalate in 0.05M H2SO4 was irradiated with the same lamps, test tube, and 
volume as photolysis procedures. The preparation of an actinometer has been described 
previously20. To a 10mL volumetric flask was added 0.5mL buffer pH 7.4 phosphate buffer, 2mL 
0.1% phenanthroline, 0.9mL 0.05M Sulfuric acid, and 0.1mL of irradiated solution. The 
absorbance of a prepared solution was measured and checked against a blank. The difference in 
optical density was converted to concentration using a calibration curve. The change in 
concentration was converted to mol/min and light output was determined by dividing this 
number by 1.2420. The calibration curve was constructed by dissolving FeSO4 in distilled water 
and diluting to a range of concentrations from 1.03x10-3 to 1.24x10-4M. Solutions were prepared 
for analysis by adding, volumes of aqueous Fe3+ to make the desired concentration, a volume of 
0.05M sulfuric acid to make the total volume 5mL, 1mL 0.1% phenanthroline, 2mL pH 7.4 
phosphate buffer, and distilled water to a total volume of 10 mL. The optical density was 
measured at 510nm.  
2.2.15 Quantum Yield Determination  
 Change in concentration over time was determined by converting absorbance of product 
to concentration using a calibration curve constructed by measuring absorbance of 
concentrations over area of interest. The slope of the curve of concentration vs time represents 
the rate of change of M/min which can be changed to mol/min by multiplying by the volume 




2.2.6 Animals:  
 Mice (Charles River Laboratories, Inc., Wilmington, MA, USA), were housed 5 per cage 
in plastic cages with food and water available ad libitum in a temperature/humidity-controlled 
environment. Animals were placed on a 12 hour light/dark cycle.  All experiments were carried 
out in accordance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals. All procedures were approved by the University of Kansas Institutional 
Animal Care and Use Committee.   
2.2.17 Brain Slices:  
 Brain slices were harvested as previously described21. In summary, mice were deeply 
anesthetized by isofurane inhalation and decapitated. The brain was then immediately removed 
and placed into ice-cold artificial cerebral spinal fluid (aCSF). The aCSF solution contains the 
following concentrations: 2.5 mM KCl, 126 mM NaCl, 1.2 mM NaH2PO4, 25 mM NaHCO3, 2.4 
mM CaCl2, 1.2 mM MgCl2, 20 mM HEPES, 11 mM D-glucose.  The pH was adjusted to the 
physiological pH 7.4.  To ensure the tissue received ample oxygen, the aCSF was continuously 
bubbled with 95% O2/5% CO2 throughout the experiment. After chilling for one minute the 
cerebellum was removed and the brain was bisected using a sterile razor blade.  One hemisphere 
of the brain was then glued to a plate against a cube of agar for support.  300 µm coronal brain 
slices were then obtained using a vibratome (Leica, Wetzlar, Germany). After obtaining a brain 
slice containing striatal tissue, it was transferred to a perfusion chamber where oxygenated aCSF 
was perfused over the slice and was heated to 34 ºC.  The slice was equilibrated for one hour 




2.2.18 Optrode fabrication  
 Optrodes were fabricated by cutting a silica capillary (40 µm ID TSP 040105 polymicro) 
and a 60 µm fiber optic to a length of 3 cm. The outer coating was removed from the capillary 
using a flame and the capillary and fiber optic were aligned. A 7µm carbon-fiber purchased from 
Goodfellow Cambridge Ltd. (Huntingdon, England) was aligned with the silica capillary and the 
fiber optic so that the carbon fiber extended ~ 3 mm beyond the fiber optic silica capillary unit. 
This was loaded into a second silica capillary (200 µm TSP 2503506 polymicro) and the unit 
was aligned with the opening of the second capillary so only the carbon fiber extended beyond 
the opening using a micromanipulator.  This was then sealed by using capillary effects to get a 
well-mixed epoxy mixture of  0.24g EPI-CURE 3234 Curing Agent (lot FCXC4114/0886GG) 
and 2.00g EPON Resin 815C (lot HADN0003/1307GG), which had been allowed to pre cure for 
an hour, into the second capillary until it was completely filled. The epoxy was allowed to cure 
for 12 hours. The unit was threaded into a glass capillary tubes (1.2 mm D.D and 0.68 mm I.D, 4 
in long; A-M System Inc, Carlsborg, WA, USA) and baked for another hour at 100 ⁰C then the 
carbon fiber was cut to ~ 30 μm. 
 
2.3 Results and Discussion 
2.3.1 Protection and deprotection of phenols 
 We decided to synthesize a very simple model complex in order to determine if it was 
possible to cleanly uncage a pHP-phenol bond. Para-cyanophenol was selected for these initial 
studies because the electron withdrawing nature of the para cyano group causes the phenolic 
hydrogen to be more acidic when compared to the unmodified phenol. This more acidic phenol 
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should mean that para-cyanophenol is an ideal leaving group partner for the pHP 
photochemistry. Compound 1 was synthesized as shown in Scheme 2.  
 
Scheme 2: Synthesis of, 4-(2-(4-hydroxyphenyl)-2-oxoethoxy)benzonitrile (Compound 1) 
 The photochemical reactivity of Compound 1 was initially studied using UV-vis by 
irradiating the compound with 300 nm light and taking aliquots of the reaction mixture every six 
minutes for measurements. As can be seen in Figure 3, as Compound 1 was exposed to 300 nm 
light, the absorbance peak at 275 nm, characteristic of Compound 1, decreased in intensity. This 
shows that a photochemically induced reaction is taking place which is consuming the starting 
material.  While this is promising because it shows that the starting material is being consumed 
after exposure to light, the UV-vis data can only give us insight into what is happening with the 
protected phenol, it cannot show was what products are being produced. In order to elucidate 
theses products H1 NMR was used. 
 
Figure 3: UV-vis study of Compound 1. There is an observed decrease in the absorbance at 275 
nm, the peak which is indicative of the phenol on the pHP protecting group, over time implying 





Figure 4: The photochemical uncaging of 1 as tracked by H1 NMR. The singlet at 5.48, 
indicative of the caged starting material, is disappearing as the reaction proceeds indicating the 
starting material is being consume. The peaks at 6.76 and 7.58, representing 4-hpaa and 4-
cyanophenol are growing in indicating that these are the two major products. 
  In order to ascertain the identity of the products the photochemical reaction of compound 
1 was tracked via 1H-NMR.  In a clean uncaging reaction taking place via the photo-favorskii 
rearrangement it would be expected that the characteristic peaks of the caged starting material, δ 
5.48, would disappear. The peaks indicative of the two main predicted products, 4-HPAA δ 6.76 
and 4-cyanophenol δ 7.68, should also appear as the reaction progressed. The H1 NMR data 
presented in Figure 4 follows these predications very well. The caged starting material 
disappeared while the two main product peaks appeared. It is also important to note that from the 
H1 NMR it appears that no secondary product peaks are appearing, implying that the reaction is 
occurring through the photo-favorskii mechanism predominately. Once it was determined that 
the reaction of Compound 1 underwent a clean photochemical uncaging reaction, the quantum 
yield of Compound 1 was determined to be 0.33 + 0.03. Overall, Compound 1 showed that it is 
possible to cleanly uncage simple acidic phenols and gave us confidence moving forward that the 




Figure 5: A comparison between the 5-chlorosalciylate and the D2 antagonist raclopride 
 Our final target, the family of D2 receptor antagonists, including raclopride, are very 
expensive compounds so we decided to pursue another, more complex, model before committing 
to the use of our actual targets. The intermediate model chosen was 5-chlorosalciylate because of 
its similarities to raclopride. As can be seen in Figure 5, 5-chlorosalciylate captures two features 
we thought would be important to the chemistry of the raclopride target: 1) The two compounds 
share a chlorine moiety that is para to the phenol group. This chlorine should capture some of the 
electronic properties of the compound of interest. 2) Both compounds have a carboxy group 
ortho to the phenol group, with an ester in the case of 5-chlorosalciylate and an amide in the case 
of raclopride. This carboxy group should help to model the sterics of the target compound.  
 The synthesis of Compound 2 is shown in Scheme 3. Unlike in the synthesis for 
Compound 1, a protection step of the pHP groups’ phenol moieties was used. This was done 
because the sterics of 5-chlorosalciylate were predicted to slow down the hetero-coupling. It was 
thought this would make the homo-coupling more likely than in the case of the para-cyanophenol 
coupling. A very small amount of Compound 3 was synthesized when the benzyl group was used 
as the protecting group; however, we were unable to succeed in removing this benzyl protecting 
group. This protecting group on the phenol of the pHP prevented the photochemistry from 
proceeding. In order to try to overcome this difficulty in synthesis two other protecting groups 
were tried, 4-methoxybenzyl and 4-nitrobenzyl. It was found that when these groups were used 
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the bromination reaction, needed to provide a handle for the coupling chemistry, either went too 
far causing over bromination or did not proceed. 
 
Scheme 3 proposed synthesis of Compound 2 
  Overall, we were able to show that it is possible to cleanly uncage a simple, acidic 
phenol in a reaction that follows the photo-favorskii mechanism in reasonable quantum yields. 
However, we were not able to successfully synthesize a more pertinent model of the target 
compounds both because of difficulties in synthesizing the protected Compound 2, likely 
because of steric issues, and difficultly in removal of the benzyl protecting group from 
Compound 2 to reach Compound 3. When alternative protecting groups were used to make the 
deprotection chemistry more favorable, it was found that the bromination chemistry was either 
not occurring at all or was over brominating. Our inability to successful synthesize Compound 2 
led us to move on from this line of work to a different, theoretically more favorable moiety. 
2.3.2 Protection and deprotection of thiols 
 This second moiety our group became interested in was thiols. Thiols have two main 
characteristics that make them a favorable target for this type of chemistry. 1) They are highly 
nucleophilic moieties meaning that the coupling chemistry should be easier to achieve. 2) Thiols 
are also a fairly acidic moiety with a pka 8.2-10 22 which make them good leaving group 




used as a group to protect thiol containing compounds such as glutathione and cysteine by 
Specht et al.23 This chemistry was shown to undergo the photo-favorskii rearrangement for the 
majority of products formed based on 1H-NMR product analysis. 23 We hoped to take this 
chemistry and apply it to a class of glutathione peroxidase inhibitors that have this thiol moiety.  
Figure 6 The two compounds to the left did not inhibit glutathione peroxidase because they did 
not have an unblocked thiol moiety. The two compounds to the right were found to be potent 
inhibitors of glutathione peroxidase because of their open thiol moieties.   
 
 The interest in this thiol moiety biologically arises from the fact that it is the active 
portion of a class of glutathione peroxidase inhibitors. Examples of these inhibitors are shown in 
Figure 6. All of these compounds share a common thiol group that has been shown 22 to be the 
biologically relevant portion of the compound for inhibition to take place. Glutathione 




Figure 7: Production of hydrogen peroxide in mitochondria. The thiol based inhibitors increase 
production by blocking glutathione peroxidase’s conversion of hydrogen peroxide to 




 If glutathione peroxidase is inhibited, the production of hydrogen peroxide, a proposed 
neuromodulator 25, 26 as well as a ROS 27, 28 , will increase. Since thiols have favorable chemistry 
for this type of photo caging reactions as outlined above, and the biological activity data 22 points 
to the thiol being vital for the biochemistry, we hypothesized that caging a glutathione 
peroxidase inhibitor was an interesting avenue to pursue. 
 
Scheme 4: Synthesis of Compound 4. 
 Mercaptosuccinic acid (MCS) is a potent glutathione peroxidase inhibitor22 that our lab 
has used in the past with success. The synthesis for a caged form of mercaptosuccinic acid is 
shown in Scheme 4. It consisted protecting the carboxylic acid groups on mercaptosuccinic acid 
by converting them to esters. This was done to prevent the bonding of 3 protecting groups to 
mercaptosuccinic acid during the coupling reaction. A SN2 coupling was then done to protect the 







Figure 8: UV-vis taken of Compound 4 at specific time intervals after exposure of the 
compound to 300 nm light. As the reaction was allowed to continue the absorbance peak 
observed broadened, which is indicative of a chemical change taking place. 
 
 Initially, the compound was exposed to 300 nm light and UV-vis spectra were taken of 
the reaction at time points 5 minutes apart. These data is shown in Figure 8. These data did not 
have a clean decrease in a single peak like the data presented above for Compound 1; however, 
there is a broadening in the absorbance observed at about 295 nm that implies a change is 
occurring in the starting material. We took this alteration to mean that a reaction was occurring 





Figure 9: The photochemical uncaging of 4 as tracked by H1 NMR. The singlet at 4.27, 
indicative of the caged starting material, is disappearing as the reaction proceeds indicating the 
starting material is being consume. While this is indicative of product disappearing there seems 
to be no product peaks appearing during the reaction.  
 
 In an attempt to elucidate the identity of these products, the reaction was tracked by H1-
NMR. As seen in Figure 9, as the reaction progresses over time the peak at 4.27, representative 
of the methylene protons on the carbon bonding the pHP group to the MCS ester is disappearing. 
This disappearance implies that Compound 4 is being consumed in the reaction. Even though the 
H1 NMR shows that the starting material is disappearing no new peaks are appearing from 
production of products. This result was confusing because it implies that the products being 
formed in the reaction are either not viewable in our chemical shift range, which is unlikely since 
they should be similar compounds to the starting material, or that there are many products being 
formed all below the limits of detection in H1-NMR. 
 In order to elucidate what was happening in this presumably complex reaction mixture, it 
was decided to track the reaction using liquid chromatography mass spectrometry (LC-MS). 
Compound 4 was exposed to 300 nm light for 10 minutes and then analyzed using a LC 
51 
 
separation coupled to an electrospray ionization source with triple quadrupole detection. When 
this experiment was done, as seen in Figure 10, a complex mixture of ions was observed. Instead 
of 3 peaks, one representing starting material, one representing the release of the leaving group, 
and one representing the expected 4-HPAA byproduct, there was a multitude of peaks present. 
We were able to identify two of these peaks, one at 16.45 minutes which corresponds to the 
starting materials mass and one at 8.94 minutes which corresponds to pHP’s mass. The fact that a 
pHP peak was observed after the reaction occurs is telling because it implies that the photo-
favorskii mechanism cannot be the only photochemical mechanism occurring. As was outlined 
above, if the photo-favorskii was the main mechanism of action, 4-HPAA would be expected to 
be the main byproduct of the uncaging, not a return of the intact pHP cage itself. Since pHP was 
found to be a major product, as determined by the mass and total ion count, we propose that the 
reaction proceeded through the mechanism presented in Figure 10b. This mechanism proposes 
that, instead of a photo-favorskii like mechanism occurring, a homolytic cleavage of the carbon 
sulfur bond occurs, forming two radicals. The pHP radical could than abstract a hydrogen and 
form pHP starting material, the peak we see at 8.94 minutes. The sulfur radical could also 
abstract a hydrogen to form the desired dimethyl-2-mercaptosuccinate product, though this 
product was not observed in the mass spectrometry data. It is also possible that both radicals are 
reacting with other species in the reaction mixture. These reactions could lead to the large 
number of species observed in the mass spectrometry data that were not predicted from our 
originally hypothesized mechanism. It is clear that a photochemically induced uncaging reaction 
is occurring; however, because of the hypothesized presence of radicals during the reaction, it is 





Figure 10: (A) The total ion count chromatogram of the reaction mixture after 10 minutes of 
exposure to 300 nm light. Instead of the three peaks expected (starting material, 4-HPAA and 
dimethyl-2-mercaptosuccinate) many peaks were observed. (B) The mass spectra of two of the 
peaks, one at 8.94 minutes which has been identified as pHP and one at 16.45 minutes which has 
been identified as starting material. (C) A proposed alternative mechanism for the photochemical 
uncaging of  dimethyl-2-mercaptosuccinate, this mechanism consists of a hemolytic cleavage 




2.3.3 An optrode for photochemistry 
 As briefly discussed above, one of the main reasons that we are interested in the pHP 
protecting group, beyond the favorable photochemical properties, is the ability to quantify the 
release of non-electroactive compounds by the measurement of the 4-HPAA byproduct. We have 
obtained preliminary data showing that it is possible to make these measurements of 
photochemical release in brain tissue; however, we have discovered there are two main 
difficulties when doing these experiments: 1) It is difficult to align the fiber optic light guide 
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with the working electrode using micromanipulators alone. 2) These experiments are difficult to 
do without using large amounts of expensive photo protected compound because of the large 
volumes and flow rates needed to keep the tissue alive. Therefore, we set out to design a device 
that can solve these problems by combining a working electrode for the electrochemical 
measurements, a fiber optic light guide for the directed delivery of light and a silica capillary for 
the direct delivery of compound. 
 
Figure 11: An inner capillary (IC) has its coating burned off and is aligned flush with an optical 
fiber (OF). Once this alignment is achieved the IC and OF are held in place by wax. A carbon 
fiber is then attached using static electricity. All of this is threaded into an outer capillary (OC) 
and the IC and OF are aligned with the end of the OC using micromanipulators. Once everything 
is aligned the OC is filled with epoxy sealing the IC and OF inside. This is allowed to cure for 12 
hours at room temperature. Once the curing process is complete the OC is threaded into a glass 
capillary and sealed in with epoxy and is then cured for 1 hour at 100 ⁰C. Once the epoxy has 
cured the carbon fiber is cut to ~ 50 μm.  
 
 The fabrication of our optrode is shown in Figure 11. The optrode consists of a 40 μm 
inner capillary, a 60 μm optical fiber, and a 7 μm carbon fiber all contained within a 200 μm 
outer capillary. This unit is then glued and sealed into a glass capillary that is 0.8 mm ID, 1.2 
mm OD. Images of the completed optrode are shown in Figure 12. The fiber optic and the inner 
capillary extend beyond the glass capillary so they can be integrated with light sources and 
pumps respectively. The inner capillary and optical fiber are located within the outer capillary in 
order to make sure the injection system and optical fiber are protected from fouling by the tissue. 
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Finally, the carbon fiber is extended beyond the outer capillary so it can be inserted into the 
tissue to make measurements.  
 
Figure 12. Images of an optrode under the microscope showing how the inner capillary and 
fiberoptic are contained within the outer capillary while the carbon fiber extends beyond the 
outer capillary. The second image shows the optrode not under the microscope showing that the 
outer capillary extends beyond the glass capillary and the inner capillary and fiber-optic extends 
beyond the glass capillary so they are accessible to be hooked up to apparatus.  
  
To examine the practicability of the electrode, flow cell experiments were conducted to 
show that the optrode could detect dopamine. Tests were also done to ascertain if fiber optic was 
able to deliver light to the electrode surface. As can be seen in Figure 13A, the optrode can detect 
3 μm dopamine in a flow cell with a CV that is indicative of dopamine. The shape of the current 
vs time plot is very similar to what is seen in a normal electrode used in our lab. This implies that 
the optrodes have the same ability to measure dopamine as standard electrodes. The second 
experiment done to characterize the electrode was a light coupling test. The fiber optic cable was 
coupled into a mercury light source that was modulated with a shutter. An experiment was done 
where the shutter was opened, coupling light into the fiber optic, which was able to guide the 
light to the electrode surface. This light caused a light artifact to appear in the current vs time and 
color plot as shown in Figure 12B. This strong one point signal is indicative of the light 
interacting with the electrode surface and producing a current due to the photoelectron effect. 
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This is indicative of the light guiding fiber optic guiding the light onto the surface of the 
electrode. 
 
Figure13. (A) Detection of 3 µM dopamine in a flow cell. The CV and current trace shape are 
consistent with what would be expected in an experiment using a normal electrode used in our 
lab. (B) A light artifact, the high current signal point peak in the current plot was observed after 
light was introduced to the fiberoptic in the optrode. This indicates that the optrode is delivering 
light to the electrode surface. 
 
 Overall, the design showed promise in that light hit around the region of the electrode and 
we were able to detect dopamine in a flow cell. However, the optrodes themselves had two 
design flaws found during this initial testing: 1) The working electrode portion was very brittle, 
this made it difficult to cut and use without breaking the electrode.2) The outer capillary was 
very large leading to tissue damage when the optrode was tested in brain slices.   
2.4 Conclusions 
 This work showed that it was possible to cleanly uncage an acidic phenol, para-
cyanophenol through a heterolytic cleavage that followed the photo-favorskii rearrangement. 
Unfortunately, we could not successfully synthesize a more pertinent model compound for our 
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targeted compounds (D2 receptors antagonist). We were successfully able to synthesize a caged 
thiol; however, we discovered that the photochemistry likely undergoes a homolytic mechanism 
involving radical formation. Since this photochemistry produced a multitude of undesired 
products, it is not a good candidate for biologically relevant experiments. 
 We were also able to successfully fabricate a combined electrode optical fiber system for 
the delivery and release of caged compounds on tissue. This served as a good proof of concept as 
this optrode was shown to be able to detect dopamine in a flow cell. It was also demonstrated 
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Chapter 3 Ex vivo measurement of electrically evoked dopamine release  
in zebrafish whole brain  
 
Portions of this chapter are reprinted with permission from Shin, M., Field, T. M., Stucky, C. S., 
Furgurson, M. N., & Johnson, M. A. (2017). Ex vivo measurement of electrically evoked 
dopamine release in zebrafish whole brain. ACS Chemical Neuroscience.Copyright 2017 
American Chemical Society." I collected a portion of the release and pharmacology data and I 
collected all of the modelling and uptake data in this chapter. 
Abstract 
Zebrafish (Danio rerio) have recently emerged as useful model organism for the study of 
neuronal function. Here, fast-scan cyclic voltammetry at carbon-fiber microelectrodes (FSCV) 
was used to measure locally-evoked dopamine release and uptake in zebrafish whole brain 
preparations and results were compared with those obtained from brain slices. Evoked dopamine 
release ([DA]max) was similar in both whole brain and sagittal brain slice preparations (0.49 ± 
0.13 µM in whole brain and 0.59 ± 0.28 µM  in brain slices). Treatment with α-methyl-p-tyrosine 
methyl ester (αMPT), an inhibitor of tyrosine hydroxylase, diminished release and the 
electrochemical signal reappeared after subsequent washout. Although no observed change in 
stimulated release current occurred after treatment with desipramine and fluoxetine in the whole 
brain, treatment with desipramine resulted in a modest decrease in uptake, suggesting that 
norepinephrine may also contribute to the signal. Uptake was inhibited more strongly following 
treatment with nomifensine compared to GBR 12909, while treatment with sulpiride, a D2 
dopamine autoreceptor antagonist, resulted in increased stimulated dopamine release in whole 
brain, but had no effect on release in slices. Interestingly, dopamine release in whole brains 
increased progressively up to an electrical stimulation frequency of 25 Hz while release in slices 
increased up to a frequency of only 10 Hz and then flattened out, highlighting another key 
difference between these preparations. We also observed a lag in peak dopamine release 
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following stimulation as well as a secondary current that prevented return to baseline, which we 
address using diffusion models and pharmacological treatments. Collectively, these results 
demonstrate, for the first time, the electrochemical measurement of dopamine release in the 
whole, intact brain of a vertebrate ex vivo and are an important step for carrying out more 
complex experiments. 
3.1 Introduction 
Zebrafish (Danio rerio) are teleosts that were initially established as a model organism in 
the 1970s by George Streisinger for the study of development 1 Recently, zebrafish have 
emerged as a desirable model for the study of neuronal function 2 in part because they 
approximate the human central nervous system more accurately than invertebrates and are easier 
to genetically manipulate than rodents 3. Moreover, the optical transparency of zebrafish larvae 
make this organism well-suited for in vivo studies in which intracellular calcium changes 4 and 
action potentials 5 can be imaged real-time. Also, the zebrafish central nervous system, when 
studied using cultured cells 6, brain slices 7, and intact brain 8, has proven amenable to 
electrophysiological measurements of neuronal firing.  
In addition to these methods, the use of electrochemistry to measure the release and 
uptake of neurotransmitters in zebrafish is just now being realized. Fast-scan cyclic voltammetry 
at carbon-fiber electrodes (FSCV) is an electrochemical technique that provides good chemical 
selectivity and sub-second temporal resolution, allowing the measurement of the release and 
uptake of electroactive neurotransmitters9. FSCV has been used extensively in rodents to 
measure the release and uptake dynamics of dopamine, an abundant catecholamine 
neurotransmitter that plays a role in many aspect of neurological function, including the control 
of intentional movement  10, cognition 11, and reward 12.  
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Recently, the release of dopamine and other neurotransmitters was measured in sagittal 
brain slices acutely harvested from zebrafish, providing important proof of concept13. However, 
it is important to note that, although analysis of slices from various neuronal systems, especially 
rodents, have yielded much information regarding the study disease state mechanisms 14 as well 
as fundamental neurotransmitter release properties 15, brain slice preparations in general have 
several drawbacks, such as cellular damage induced at the surface of the slice 16 and difficulty in 
capturing entire neuronal pathways 17. The use of intact brains could mitigate these problems by 
decreasing the amount of tissue damage and leaving the neuronal pathways intact, thereby 
allowing remote stimulation of the pathway and eliminating the release of interfering 
neurotransmitters and neuromodulators that would be present upon local stimulation. 
Additionally, constant potential amperometry has recently been used to measure stimulus evoked 
dopamine release in zebrafish larvae18. However, to our knowledge, FSCV measurements of 
neurotransmitter release within the intact brains of adult zebrafish have not yet been reported in 
the literature; thus, the measurement of locally-stimulated dopamine release from acutely 
harvested, intact zebrafish brains, and comparison of these measurements with those from brain 
slices, represents a critical first step.    
Here, we describe measurements of dopamine release and uptake in whole, intact 
zebrafish brains with FSCV. Furthermore, we compare these measurements to those obtained in 
sagittal and coronal brain slices. We found that, when the working electrode is properly placed 
by reference to the external features of the removed brain, electrically evoked dopamine release 
and uptake is easily measured in zebrafish whole brain ex vivo. The cyclic voltammograms (CV) 
obtained suggest that the primary neurotransmitter measured is dopamine, and that 
norepinephrine may also be released. Moreover, we confirmed the presence of dopamine with 
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pharmacological agents that alter dopamine release and uptake. Some of the unique 
characteristics of release and uptake curves are also discussed. These results support the use of 
FSCV in ex vivo whole brain preparations as a useful analytical tool for measuring 
neurotransmitter release and uptake in zebrafish.  
3.2 Methods 
3.2.1 Chemicals.  
 Dopamine, α-methyl-p-tyrosine methyl ester (αMPT), nomifensine, and (±) sulpride, 
were purchased from Sigma-Aldrich (St. Louis, MO). All aqueous solutions were made with 
purified (18.2 MΩ) water. A modified artificial cerebrospinal fluid (aCSF) for zebrafish 
consisted of 131 mM NaCl, 2mM KCl, 1.25 mM KH2PO4, 20 mM NaHCO3, 2mM MgSO4, 10 
mM glucose, 2.5 mM CaCl2·H2O, and 10mM HEPES, and the pH was adjusted to 7.4. 
Dopamine stock solutions were prepared in 0.2 M perchloric acid and were diluted with aCSF 
without glucose to 1 µM for calibrations. Solutions of 50 µM aMPT, 10 µM nomifensine, and 10 
µM sulpride, were prepared the day of each experiment.  
3.2.2 Electrochemical Measurements.  
 Cylindrical carbon-fiber microelectrodes were fabricated as previously described. Briefly, 
7 µm diameter carbon fibers (Goodfellow Cambridge LTD, Huntingdon, UK) were aspirated 
into a glass capillary tubes (1.2 mm D.D and 0.68 mm I.D, 4 in long; A-M Systems, Inc, 
Carlsborg, WA, USA). Loaded capillaries were then pulled using a PE-22 heated coil puller 
(Narishige Int. USA, East Meadow, NY) and carbon fibers were trimmed to a length of 30 µm 
from the pulled glass tip. To seal the carbon fibers, electrodes were dipped into epoxy resin 
(EPON resin 815C and EPIKURE 3234 curing agent, Miller-Stephenson, Danbury, CT, USA) 
and cured at 100 ̊C for 1 hour. The electrodes were soaked in isopropanol for 10 minutes, and the 
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electrode surface was electrochemically pretreated by scanning with the waveform –0.4 V to 
+1.3 V back to –0.4 V at a frequency of 60 Hz for 15 min followed by 10 Hz for 10 min. 
Electrodes were then backfilled with 0.5 M potassium acetate for electrical connection. A 
chlorided Ag wire was used as the Ag/AgCl reference electrode. Data were collected and 
analyzed using an electrochemical workstation consisting of a Dagan Chem-Clamp potentiostat 
(Dagan, Minneapolis, MN, USA), modified to allow decreased gain settings, a personal 
computer with TarHeel CV software (provided by R.M. Wightman, University of North 
Carolina, Chapel Hill, NC, USA.), a UEI breakout box (UNC chemistry department electronics 
design facility, Chapel Hills, NC), and two National Instruments computer interface cards (PCI 
6052 and PCI 6711, National Instruments, Austin, TX). The waveform was applied every 100 ms 
to the electrode at a scan rate of 400 V/s. Electrodes were calibrated with a 1 µM dopamine 
solution . To evoke dopamine release both in whole brain and brain slices, multiple stimulus 
pulses (25 pulses, 2 ms, 350 µA) was applied for 0.5 s at 5 s unless mentioned otherwise. This 
stimulation was applied by two tungsten electrodes 200 µm apart. A recovery time of 10 min 
between stimulations was used for both whole brain and brain slices experiments. All statistical 
analysis was done using GraphPad Prism 6 (GraphPad Software, Inc , La Jolla, CA, USA). All 
data are reported as a mean plus or minus the standard error of the mean.  
3.2.3 Zebrafish.  
 All animal procedures were approved by the University of Kansas Institutional Animal 
Care and Use Committee. Zebrafish were housed in the Molecular Probes Core of the Center for 
Molecular Analysis of Disease Pathways at the University of Kansas. Zebrafish were euthanized 
by rapid chilling, and then decapitated. Brains were harvested under a dissection stereoscope 
(Leica Microsystem, Bannockburn, IL, USA) and transferred to a superfusion chamber in which 
66 
 
they were kept viable by continuous flow of oxygenated (95% O2 and 5% CO2) aCSF maintained 
at a temperature of 28ºC. The brain was immobilized by placement of a nylon mesh harp on top. 
Brains were allowed to equilibrate in the chamber for 1 hour prior to collecting measurements. 
For brain slice preparation, harvested brains were suspended in 2% low gelling point agarose 
(agarose type VII-A, Sigma-Aldrich, St Louis, MO, USA) prepared in 50% distilled water and 
50% aCSF. After hardening, a block of agarose containing the brain was cut off and glued onto a 
specimen disk and fastened in the buffer tray of a vibratome (Leica Microsystem, Bannockburn, 
IL, USA). The tray was filled with ice cold oxygenated aCSF and kept at 2-4°C during slicing. 
Sagittal and coronal slices, 350 µm thick, were transferred to the perfusion chamber and were 
allowed to equilibrate for 1 hour prior to collecting measurements.  
3.2.4 Statistical Analysis. 
  Error bars represent mean ± SEM. Graphpad Prism version 4.03 was used to carry out 
statistical analyses.   
 
3.3 Results and Discussion         
  
3.3.1 Evoked dopamine release in zebrafish.  
 A photograph of a viable whole brain acutely harvested from an adult zebrafish is shown 
in Fig. 2A. The brain is situated ventral side face up to provide easier access to the subpallium in 
the telencephalon, a region of the brain that contains dopaminergic innervation 19. The carbon-
fiber microelectrode and the stimulation electrodes were micro-manipulated into place by 
referencing the external features of the ventral side of the brain. The carbon-fiber microelectrode 
was positioned 100 µm laterally from the medial olfactory tract (MOT) and inserted 280–300 µm 
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deep. The region was stimulated locally with a biphasic stimulus pulse regimen in which 25 
pulses, 2 ms duration and 350 µA current, was applied. Application of this regimen resulted in 
the release of dopamine detected by FSCV at the carbon-fiber microelectrode (Fig. 2C). A 
stimulated release plot (concentration versus time profile), sampled from the color plot at the 
horizontal dotted line, is located above the color plot. A cyclic voltammogram (CV), sampled at 
the vertical dashed line of the color plot, serves as electrochemical evidence that the 
neurotransmitter released is dopamine.  
 
 
Figure 1 Dopamine release as a function of working electrode placement. The working electrode 
was moved superior and inferior from the ventral telecephelon. Dopamine release disappeared in 
both directions, as indicated by the disappearance of the indicative CV. 
 
In order to determine how spatially resolved our method is we kept the stimulation 
electrode stationary and moved the working electrode inferior and superior from the MOT as 
well as dorsally. We found that as the electrode was moved away from the MOT both superior 
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and inferior the release event was no longer observed. We also moved the working electrode up 
and down 30 µm increments and discovered that the dopamine was found consistently in a 60 
µm region (data not show). These results suggest that the region that is dopamine rich is specific 
( Fig 1). 
  
Figure 2. Electrically-evoked dopamine release in zebrafish whole brain and sagittal brain slices. 
Images of a whole brain (A) and a sagittal slice (B) indicate the placement of carbon-fiber and 
stimulus electrodes in the ventral telencephalon. Representative data of evoked dopamine release 
in a whole brain (C) and a sagittal brain slice (D) are shown. For C and D, the stimulated release 
plots (top) were sampled at the horizontal white dashed lines and the cyclic voltammograms 
(insets) were sampled at the vertical white dashed lines of the color plots. The stimulation times 
are indicated on the release plots by the time between the dashed lines. The CVs (dotted lines) 
are overlaid with sample voltammograms from the flow cell represented by the solid line.  
 
For comparison, dopamine release was also measured in acutely harvested sagittal brain 
slices (Figs. 2B and C). The stimulation and working electrodes were micro-manipulated into 
position at the ventral telencephalon. Dopamine release was evoked locally using the same 
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stimulation parameters used in the whole brain. Both CV and current versus time plots are 
similar to those obtained in the whole brain preparation. In the representative raw data, [DA]max 
increased until a peak concentration of about 0.5 µM was measured ~2 s after stimulus 
application. Current then decreased as uptake occurred. Observation of the color plots suggest 
that other electroactive species were not released in substantial quantities. Also, electrically 
evoked [DA]max was consistent throughout each recording session. Dopamine release 
measurements in both preparations were collected for one hour and compared.  
Data pooled from multiple whole brains and brain slices reveal that, under equivalent 
stimulation conditions, average [DA]max was not significantly different in whole brain and slices: 
0.41 ± 0.07 µM in whole brains and 0.54 ± 0.13 µM in slices (p = 0.40, n=9 slices and 9 brains, 
t-test). The concentration of dopamine release evoked by either single or multiple stimulus 
pulses, both in vivo and ex vivo, has been reported extensively in the literature. For example, 
application of single pulses in mouse brain slices resulted in 1.43 ± 0.11 µM (striatum) 20, 1.42 ± 
0.14 µM (nucleus accumbens core), and 1.40 ± 0.19 µM (caudate putamen) 21. Multiple 
stimulation pulses were applied in vivo to evoke dopamine release in the rat striatum at a 
reported peak concentration of 1.04 ± 0.14 µM22. Recently, Jones et al.(23) found dopamine to be 
released in zebrafish sagittal slices at a peak concentration of about 100 nM following 
stimulation with 20, 4-ms duration pulses applied at a current of 500 µA and an application 
frequency of 60 Hz. In any case, it appears from our results that less dopamine is released in 





Figure 3. The effect of DAT inhibition on dopamine overflow in whole brain (A) sagittal (B) 
and coronal (C) brain slices. Dopamine release was measured before and after 10 µM 
nomifensine was administered to each preparation. The current versus time profiles show that 
dopamine uptake was diminished. Dopamine overflow after nomifensine was added was 
significantly increased in whole brain (p < 0.05, n = 4 brains, t-test), sagittal slices (p <0.05, n = 
5 slices, t-test) and coronal slices (p<0.05, n = 4, t-test) (D). Stimulation time is indicated on the 
release plots by the time between the dashed lines. 
 
3.3.2 Effect of pharmacological agents on evoked dopamine release.  
 Extracellular dopamine levels are tightly regulated by the dopamine transporter (DAT), a 
membrane-bound protein that transfers dopamine molecules from the extracellular space to the 
intracellular space within neurons 23. The stimulated release plot reveals that, similar to the 
mammalian brain, dopamine is immediately taken up after release. Based on previous 
measurements in brain slices from mice that lack the DAT 24, it is likely that dopamine is 
actively taken up and that the decrease in current is not the result of diffusion away from the 
electrode.  
Additional pharmacological studies were conducted in which whole brain preparations, 
along with sagittal and coronal slices, were treated with 10 µM nomifensine (Fig. 3), a well-
established dopamine uptake inhibitor23. As a result, the rate of dopamine uptake was sharply 
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diminished, indicated by the decreased slope of the stimulated release curves after peak 
dopamine release. This treatment resulted in a ~130% increase in [DA]max in the whole brain 
preparation (Fig. 2A: pre-drug, 0.34 ± 0.14 µM; post-drug, 0.79 ± 0.22 µM, p < 0.05, n =  4 
brains, t-test). A similar effect was observed in sagittal slices, with [DA]max increasing ~100% 
(Fig. 2B: pre-drug, 0.49 ± 0.13 µM; post-drug, 0.97 ± 0.18 µM, p < 0.05, n = 5 slices , t-test) and 
in coronal slices, increasing ~100 % ( Fig 2C: pre-drug 0.42 ± 0.11 µM ; post-drug, 0.82 ± 0.13 
µM, p < 0.05, n = 4 slices, t-test). Our measurements also revealed a nearly complete attenuation 









Figure 4. The effect of DAT inhibitors nomifensine and GBR 12909 on dopamine release in the 
whole brain. (A) Representative stimulated release plots are shown for different concentrations 
(0, 1, 5, 30, 1000 nM) of nomifensine perfused over whole brain preparations. Stimulation time 
is indicated on the release plots by the time between the dashed lines. (B) Effect of nomifensine 
on dopamine release/uptake in whole brain. No effect on [DA]max was observed (p=0.38, one-
way ANOVA, n=3 brains); however, a significant overall effect on the 1st order rate constant (k) 
was found (p < 0.005, One-way ANOVA, n=3 brains, 5, 10, 30 and 1000 nM, tukey post hoc, * 
p<0.05, ** p<0.005 when compared to 0 nM). (C) Treatment with 10 μM GBR-12909 resulted in 
a significant increase in [DA]max (* p < 0.05, t-test, n=5) and a significant decrease in the 1
st 
order rate constant for uptake (* p < 0.05, t-test, n = 5). 
 
 To investigate its effects in more detail, whole brain preparations were treated with 
increasing concentrations of nomifensine (1, 5, 30, and 1000 nM). The data were analyzed for 
changes in concentration as well as uptake. For each plot, the uptake curve was fit to the first 
order exponential decay equation, [DA] = [DA]maxe
-kt , where [DA] is the concentration of 
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dopamine at any given time, [DA]max is the experimentally determined maximum dopamine 
concentration, k is the first order rate constant for decay, and t is time 25. In order to fit the data, 
[DA]max was held at the experimentally determined value and k was allowed to float. The data 
were fit up to the 80% signal decay point and fit was determined to be good if R2 > 0.90. The 
baseline was corrected using differential subtraction in order to remove the secondary signals 
observed after the main release event.  
A dose dependent increase in the attenuation of the reuptake was observed after the 
application of nomifensine (Fig. 3B, p < 0.005, one-way ANOVA, n = 3 brains)(Fig. 4B). 
Moreover, [DA]max appeared to increase, although this trend was not quite statistically significant 
(one-way ANOVA, p = 0.11). We also treated whole brain preparations with 10 µM GBR 12909, 
a selective dopamine uptake inhibitor, and found a significant increase in dopamine release, 
coupled to a significant decrease in the rate constant for uptake, similar to the findings of Jones 
et al. (Fig 3C; p< 0.05, t-test, n = 5). Both nomifensine and GBR 12909 are both effective in 
zebrafish, but DAT in zebrafish may be more sensitive to nomifensine than GBR 12909.     
 In order to identify signal contributions from norepinephrine or serotonin, two other 
common biogenic amine neurotransmitters, 10 µM desipramine 26, a selective norepinephrine 
uptake inhibitor, and 10 µM fluoxetine 27, a selective serotonin uptake inhibitor, were perfused 
over ex vivo whole brain preparations (Fig 5A and B). These treatments resulted in no 
statistically significant change in [DA]max (Fig 5C: desipramine pre-drug 0.43 + 0.08 µM; post-
drug 0.50 ± 0.09 µM; p = 0.60, n= 5 brains, t-test and fluoxetine pre-drug 0.27 + 0.05 µM, post-
drug 0.33 ± 0.04 µM p = 0.35, n= 5 brains, t-test). The rate of uptake for both drugs was also 
compared using the first order rate constant for the decay of the dopamine signal as outlined 
above. Fluoxetine had no significant effect on the reuptake (Fig 5C: pre-drug 0.24 ± 0.02 s-1, 
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post-drug 0.20 ± 0.01 s-1 p = 0.14, n = 5 brains). Desipramine, on the other hand, had a 
significant effect on uptake (Fig 5C: pre-drug 0.22 ± 0.04 s-1, post-drug  0.13 ± 0.01, p< 0.05, t-
test, n = 5 brains).  
The effect of desipramine on signal decay suggests that norepinephrine also makes up a 
component of the signal. Although the quantitative determination of the relative contributions of 
dopamine and norepinephrine is beyond the scope of this particular work, we speculate that 
dopamine is present in greater amount based on the following observations. First, the peak 
current observed following stimulation is unaffected by treatment with 10 µM desipramine (Fig. 
4) yet is increased by the same concentration of nomifensine (Fig. 3). Given that the inhibition 
constants (Ki) are in the low nM range for nomifensine at the dopamine and norepinephrine 
transporters28 and also for desipramine at the norepinephrine transporter29, dopamine and 
norepinephrine uptake should be almost completely inhibited. Thus, differences in measured 
peak current between these two drug treatments would reflect differences in release between 
dopamine and norepinephrine since diffusion alone is insufficient to substantially decrease 
measured extracellular levels on the timescale of our measurements (20 s)30. The fact that the 
high concentration of desipramine used resulted in a relative modest inhibition of uptake 
(decrease of ~40%) while the same concentration of nomifensine completely abolished uptake 
further supports this concept. Second, anatomical data obtained from morpholino knockdown 
experiments in zebrafish larvae suggest that tyrosine hydroxylase-expressing neurons projecting 
into the forebrain are mostly dopaminergic31  Finally, work by Shang et al.32 and Jones et al.33 
suggest that dopamine is the primary catecholamine released in this brain region. Clearly, more 
work needs to be done to quantify the relative amounts of dopamine, norepinephrine, and other 
neurotransmitters released in the telencephalon and other brain regions. However, we can 
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conclude from this work that extracellular dopamine levels are tightly regulated by DAT in the 
telencephalon immediately after release and that ex vivo whole brain preparations can be used to 
measure locally-stimulated dopamine release.  
 
Figure 5. The effects of serotonin transporter (SERT) and norepinephrine transporter (NET) 
inhibition on dopamine release in whole brains. (A) Stimulated release plots before and after 
perfusion with 10 µM desipramine. (B) Stimulated release plots before and after perfusion with 
10 μM fluoxetine. (C) Comparison of [DA]max and uptake rate constant (k) before and after 
perfusion with desipramine and fluoxetine. No significant changes in release were noted (p= 
0.595 and 0.347 for desipramine and fluoxetine, respectively, t-test, n=5). A significant 
difference in uptake was observed for desipramine (* p<0.05, t-test, n=5) while no significant 
change was noted for fluoxetine (p= 0.14, t-test, n =5). Stimulation time is indicated on the 
release plots by the time between the dashed lines. 
 
To obtain further confirmation of neurotransmitter identity, we examined the effect of α-
methyl-p-tyrosine methyl ester (αMPT), which inhibits tyrosine hydroxylase and blocks 
monoamine neurotransmitter synthesis, (Fig. 6A). Release was electrically-evoked and measured 
every 10 minutes. Upon stabilization of the dopamine signal, brains were perfused with 50 µM 
αMPT and, approximately 2 hours later, the observed signal was greatly diminished (pre-drug, 
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0.56 ± 0.08 µM; post-drug, 0.14 ± 0.07 µM, p < 0.005, one-way ANOVA). To ensure that this 
disappearance of release was not due simply to loss of neuronal viability, the drug was washed 
out, and release re-appeared approximately 1 hour later (washout, 0.51 ± 0.10 µM, p = 0.40, one-
way ANOVA), indicating that neurotransmitter release was not significantly different than 
before the drug was added (Fig. 6B). These measurements, taken in conjunction with the uptake 
inhibition experiments, further indicate that the neurotransmitters detected are catecholamines, 
and suggest that other classes of electroactive neurotransmitters, such as serotonin and histamine, 








Figure 6. The effect of dopamine synthesis inhibition on stimulated release. (A) Representative 
data of stimulated dopamine release before (left) and after (center) administration of 50 µM 
αMPT. Dopamine release reappeared after a 1-hour washout with drug-free buffer solution in the 
same recording session (right). Cyclic voltammograms for each step (inserts) confirm the release 
of dopamine. The sharp dip in current prior to the faradaic peak is an artifact occurring due to 
stimulation. (B) Evoked dopamine release, measured after 2 hours of treatment with αMPT was 
significantly decreased (n=5, p < 0.01, one way ANOVA, tukey post hoc test *p < 0.05 ). 
Dopamine release after washout was not significantly different from the pre-drug measurement  
(p = 0.40, one way ANOVA, n=5). Stimulation time is indicated by the dotted lines. 
 
 Dopaminergic terminals in the mammalian striatum possess D2-family dopamine 
autoreceptors that serve as a regulatory feedback mechanism for dopamine release23. To 
determine if a similar self-regulatory mechanism is present in dopaminergic terminals of the 
subpallium, we perfused whole brain ex vivo  preparations with 10 µM sulpiride, a D2-family 
dopamine receptor inhibitor (Fig. 7A). Approximately 1 hour after addition of drug, dopamine 
release increased by about 80% (pre-drug, 0.41 ± 0.12 µM; post-drug, 0.74 ± 0.13 µM, p < 0.05, 
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t-test). Thus, D2 receptors are also present in the zebrafish brain and appear to serve a similar 
regulatory function. However, given that the circuitry is still intact in the whole brain 
preparation, it is also possible that sulpiride may enhance the release of dopamine by antagonism 
of dopamine receptors located not only presynaptically, but also at other locations within the 
brain 34.  
To determine if autoregulation by D2 receptors occurs specifically at terminals, 
electrically-evoked dopamine release was measured in the subpallium of sagittal and coronal 
brain slices before and after sulpiride treatment (Fig. 7B). The slicing process could at least 
partially disrupt the ascending dopaminergic pathway from the diencephalon to the subpallium, 
leaving only presynaptic terminals without dopaminergic soma 19a, 19b. In sagittal slices, [DA]max 
appeared to increase upon drug treatment, but this increase was not statistically significant (pre-
drug, 0.33 ± 0.12 µM; post-drug, 0.68 ± 0.29 µM, p = 0.13, n = 5 slices, t-test). Additionally, 
[DA]max also did not increase in coronal slice preparations (pre-drug, 0.35 ± 0.12 µM; post-drug, 
0.38 ± 0.10 µM , p = 0.47, n = 5 slices, t-test). Our results suggests that, while there is an effect 
on D2 receptors in whole brains, this effect is disrupted in slice preparations. The reason for this 
lack of effect in fish is not well-understood; however, it is possible that the D2 receptors are not 
located presynaptically, but rather on the soma 34. Given that D2 receptors are also found on the 
cell bodies and axon in rodents, this arrangement would not be unprecedented in zebrafish.35  
Another possibility is that the slicing process induces damage to the terminals. Additional studies 






Figure 7. Effect of sulpiride treatment on dopamine release. Evoked dopamine release measured 
in (A) whole brain, (B) sagittal slice, and (C) coronal slice before and after treatment with 10 µM 
sulpiride. (D) Dopamine release significantly increased in whole brains (n=5, p < 0.05, t-test), 
but did not significantly increase in sagittal and coronal slices after drug treatment (p = 0.13 and 
p = 0.47, respectively, t-test, n= 5). Stimulation times are indicated by vertical lines on release 
plots. 
 
3.3.4 Kinetics of neurotransmitter release and uptake.  
 The dopamine release curves in zebrafish whole brain preparations have several 
interesting characteristics: (1) the curves have a tendency to not return to baseline levels after the 
release event, (2) [DA]max is observed to occur a certain amount of time after the end of the 
electrical stimulation, a phenomenon known as overshoot (ΔtO), and (3) dopamine release 
sometimes appears to occur a very short time after electrical stimulation is initiated, a 
phenomenon known as lag (ΔtL). Figure 8A illustrates the concepts of overshoot and lag.   
In addressing the first point, it was observed from the αMPT measurements that, after 
application of the inhibitor, the signal observed after the release event was greatly diminished 
(Fig 4). This phenomenon points to the non-return to baseline being related to the dopamine 
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initially released and not some secondary release events. From inspection of the CVs, it appears 
unlikely that the compound being detected is dopamine A chemical species we had considered 
was 3,4-dihydroxyphenylacetic acid (DOPAC). We had initially hoped to differentiate and 
identify this component using principal component analysis (PCA)36; however, PCA was 
unreliable in distinguishing between ascorbate, DOPAC, and dopamine in the zebrafish whole 
brain. This unreliability is probably due to the similarity of the compounds in the training set 
coupled with the complexity of the matrix. Further experiments will be required to completely 




Figure 8 [DA]max, lag time (ΔtL), and overshoot time (ΔtO). The concept of lag and overshoot is 
illustrated in (A). Lag (ΔtL) is the time after the stimulation begins until dopamine release is 
observed. Overshoot (ΔtO) is the time after the stimulation ends until [DA]max is reached. The 
duration of stimulation is indicated by the dark line below the release plot. The effect of 
increasing stimulation frequency on [DA]max (B) and ΔtO (C) is shown. Linear regression 
analysis showed that both parameters increased with respect to frequency with non-zero slopes 
(B, slope ≠ 0 p < 0.05, R2 = 0.725 ; C, slope ≠ 0 p < 0.005, R2 = 0.908 respectively).   
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 In addressing points (2) and (3), it is important to note that overshoot and lag are 
phenomena also observed in rodents both in vivo and ex vivo 37. The concepts of overshoot and 
lag are explained by the tendency for released dopamine to diffuse from synapse to the electrode; 
thus, we hypothesize that the time needed for this diffusion leads to ΔtO and ΔtL (Fig 8A) 
38. In 
order to examine the possible relationship between diffusion and ΔtO and ΔtL in zebrafish whole 
brain, the stimulation frequency was varied from 10 to 60 Hz while other stimulation parameters 
were held constant (120 pulses, 350 µA, 4 ms). If simple diffusion is all that is involved, it would 
be expected that ΔtO and ΔtL would be similar in magnitude and would remain constant while 
stimulation parameters change. 38a, 39 This is because in the so called diffusion gap model 
(Equation 1), diffusion is assumed to be independent of any variable except the distance between 




=  𝐷 
𝜕2[𝐷𝐴]
𝜕𝑥2
+  [𝐷𝐴]𝑝𝑓 − 
𝑉𝑚𝑎𝑥[𝐷𝐴]
[𝐷𝐴] + 𝐾𝑀
 (𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 1)  
 
In this equation, Vmax and KM are the Michaelis–Menten parameters, f is stimulation frequency, 
[DA] is the concentration of dopamine at any given point in time, [DA]p is the amount of 
dopamine release per electrical stimulus pulse, a parameter that is corrected for uptake and 
electrode performance 40, and D is the diffusion coefficient of dopamine. The first term on the 
right side is from Fick’s Second Law41 and accounts for diffusion of dopamine to the electrode, 
the second term accounts for the total amount of dopamine released, and the third term accounts 
for dopamine uptake40  
When the model is applied, a gap width is used that represents the distance between the 
electrode and the point of release38a. As this gap increases, the lag and overshoot should increase 
83 
 
by approximately equal amounts. On the other hand, if the gap remains the same the lag and 
overshoot should be approximately constant.  We observed that, as the stimulation frequency 
was increased and the electrode was held in place, both concentration and ΔtO increased in a 
linear fashion (slope ≠ 0, p < 0.05, R2 = 0.73; slope ≠ 0 p < 0.005, R2 = 0.908 respectively, Figs. 
8B and C). As [DA]max is increasing, ΔtO is also increasing. This result directly contradicts the 
prediction of the diffusion gap model that ΔtO should remain constant
38a. It is also important to 
note that, in the vast majority of traces, we did not observe a ΔtL greater than the 100 ms 
temporal resolution of our method (data not shown), which also points to the diffusion gap model 
as not holding; therefore, another model must be considered.   
 This phenomenon of ΔtO being present and independent of ΔtL, and sensitive to the 
change in stimulation parameters, has been observed by Taylor et al. 42 in rats treated with 
nomifensine. In particular, as dopamine concentration increased due to inhibition of DAT, ΔtO 
also increased while ΔtL was nonexistent. They explained this phenomenon through a restricted 
diffusion model38a. Briefly, this model assumes that dopamine needs to diffuse to the electrode 
through tissue, so that that diffusion will not be unhindered, but rather will be interfered with by 
various characteristics of the tissue such as tortuosity43 or absorption to specific sites in the 
tissue44. During a release event in the absence of drug, reuptake is much faster than the restricted 
diffusion so the dopamine that is restricted gets uptaken before it has a chance to move to the 
electrode, resulting in a small or nonexistent ΔtO. However, after nomifensine treatment, since 
uptake is significantly slowed, the restricted dopamine molecules are able to diffuse to the 
electrode for a relatively long time and ΔtO becomes large.  
In zebrafish, it is unclear what the amplitude of a naturally occurring transient is; 
however, we propose that, in the case of stimulated release, the amount of dopamine released is 
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so great that DAT becomes saturated. This saturation causes dopamine to remain in the tissue for 
a long period of time. During this time, it can diffuse, resulting in the large ΔtO we observe. 
More experiments are needed to verify this hypothesis; however, our data clearly show that, in 
zebrafish, the issue of diffusion and its role in regulation of dopamine concentration is complex.   
3.3.5 Effect of stimulation frequency on evoked dopamine release.  
 The degree of dopamine release is determined, in part, by the number of stimulus pulses 
and the frequency (number of biphasic pulses applied per second) 45. Initially, to determine if 
alteration of stimulation frequency impacts dopamine release similarly in zebrafish, evoked 
dopamine both in whole brain and sagittal slices was measured and compared at frequencies 
ranging from 5 Hz to 25 Hz while other stimulus parameters were held constant (120 pulses, 4 
ms, and 350 µA; Fig. 8). 
 We found a trend of increasing dopamine release up to a frequency of 25 Hz in whole 
brain. Although there appears to be a slight curvature, linear regression analysis revealed a strong 
correlation coefficient of linearity (R2=0.96) and also a significantly non-zero slope (p = 0.003). 
In slices, dopamine release increased at 10 Hz; however, beyond 10 Hz, the curve flattened out 
(R2=0.17). The overall slope of this curve did not significantly deviate from zero (p = 0.49). The 
difference in curves may suggest that the preparation impacts the availability of vesicles for 
release. Indeed, progressively diminishing increases of dopamine release 14e were observed in 
rodent brain slices and linear increases were observed in vivo 46 when stimulation frequency was 
increased. While the causes underlying these differences are not known, it is possible that higher 
stimulation frequencies result in mobilization of reserve pool vesicles, as our previous results in 
striatal mouse brain slices have suggested 14e. In fact, this decrease in release at higher 
frequencies was exaggerated in transgenic R6/2 mice, which are commonly used to model 
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Huntington’s disease (HD). Our previous results have suggested that this decrease is likely due 
to a diminished reserve pool in R6/2 mice. In the future, it will be interesting to determine if 
these differences between slices and whole brain arise from a diminished reserve pool or have 
some other cause.         
 
Figure 9. Effect of stimulation frequency on dopamine release. The stimulation frequency was 
increased while stimulation pulses and width were kept constant (120 pulses, 4 ms pulse 
duration). Evoked dopamine release was measured both in whole brain and sagittal slices. A 
linear regression was done for both preparations. The whole brain data had a significant non zero 
slope (R2 = 0.96, p = 0.003) while the slice preparation was found to have no significant slope 
(R2 = 0.17, p = 0.49).  
 
3.4 Conclusion  
We have shown that dopamine release can be easily measured with FSCV in the 
subpallium of zebrafish whole brain. This preparation offers the advantage of keeping the whole 
brain intact, thereby preserving the three-dimensional neuronal circuitry and offering the future 
possibility of measuring release evoked by stimulation of pathways. Similar to slices, 
extracellular dopamine levels are tightly regulated by uptake through the DAT. Our results also 
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demonstrate that uptake is inhibited by nomifensine in both brain slice and whole brain 
preparations.  
Importantly, in their recent paper, Jones et al. showed that evoked neurotransmitter 
release could be easily measured in slices13. Our work has not only built upon these findings, but 
it has also revealed other release characteristics that are apparently not found in zebrafish sagittal 
slice preparations. We have identified important differences between slices (sagittal and coronal) 
and whole brain. For example, even though D2 autoreceptors regulate dopamine release in whole 
brain and sagittal slice preparations, similar to that observed in rodents, D2 antagonism has no 
effect in slices. Moreover, stimulated release in sagittal slices responded differently to increasing 
stimulation frequency compared to release in whole brain. Finally, stimulated release plots in the 
whole brain preparation had interesting features, including a tendency to not return to baseline 
following the stimulated release of dopamine and a propensity for dopamine release to continue 
even after the end of the electrical stimulus. It is apparent that these processes reflect 
complexities in zebrafish neuronal function that must be sorted out with additional studies. 
Moreover, our studies reveal not only that release measurements in whole brain is a viable option 
that may be of particular use in studying circuit function, but also that there are differences 
between whole brain, coronal slices, and sagittal slices that should be addressed before moving 
forward.     
In summary, these results represent an important step toward more complex studies, such 
as FSCV experiments that make use of remote stimulation in zebrafish whole brain and 
measurements of dopamine release in vivo. Furthermore, the expanded use of this model 
organism will allow researchers to exploit the genetic advantages of zebrafish in the analysis of 
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Chapter 4 Chemotherapy Treatment in Zebrafish 
I collected a portion of the release data and I independently collected the Atomic absorption and 
modelling data 
Abstract 
 In this chapter, we present work on the effects of chemotherapy treatment on zebrafish 
dopamine neurotransmission. We treated zebrafish with 5-fluorouracil and carboplatin either 
through their food or their habitat water. It was found that both drugs had an effect on the release 
in zebrafish whole brains ex vivo. A difference between treatment pathways was also discovered. 
We showed that platinum did not accumulate in the brain after carboplatin treatment. Finally, we 
showed that there was no significant difference in uptake between control and treated zebrafish.  
4.1 Introduction 
Post chemotherapy cognitive impairment, also known as ‘chemobrain,’ is a neurological 
condition characterized by a decrease in higher level cognitive and executive function well after 
the conclusion of the treatment regime1. Although the underlying causes of chemobrain are not 
well understood, mechanisms that have been proposed include chemotherapy-induced DNA 
damage, disruption of vascular blood flow in the brain2, inflammatory responses to reactive 
oxygen species3, 4 , brain protein modification5, 6 and impairment of neurotransmitter signals7, 8.  
Recent in vivo studies of chemobrain have primarily made use of rats and mice9. For 
example, in our own work, we used fast-scan cyclic voltammetry at carbon-fiber microelectrodes 
(FSCV) to show that dopamine and serotonin release and cognitive performance were impaired 
in rats treated with carboplatin8, a chemotherapeutic agent commonly used in the treatment of 
cancers of the head, neck, breast, and lung10, 11. Although rodents have shown tremendous utility 
in understanding the cellular processes that underlie chemobrain, their use has drawbacks, 
including chemotherapy regimen treatment times typically on the order of weeks, the 
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requirement of i.v. injection of many chemotherapeutic agents, and the need for larger quantities 
of study compounds to be evaluated as potential therapies. These disadvantages make the 
evaluation of chemotherapeutic agents on neuronal function, as well as the testing of potential 
therapies, more difficult by decreasing throughput and increasing costs.    
The zebrafish (Danio rerio), a teleost originally used to study development, has recently 
emerged as a useful model of neurochemical signaling12, 13 and toxicology14, 15. As a model of 
neuronal function, zebrafish represent an ideal compromise between brain complexity, with 
about ~10 million cells16, and small size, which allows ex vivo studies of whole brain in a 
perfusion chamber 17. Zebrafish are useful for toxicological evaluation studies because dosing 
often requires only adding agents to the water or food, and behavioral and neurochemical 
analyses can be carried out with greater throughput18, 19 . 
Recently, our group demonstrated the feasibility of using zebrafish whole brain as a 
preparation for measuring dopamine release and uptake with FSCV 17. In this work, we extend 
the application of this preparation toward the evaluation of carboplatin on dopamine release and 
uptake properties. Zebrafish were administered chemotherapeutic either by addition to their 
habitat water or their food and then dopamine release and uptake was quantified in whole brain.  
This study revealed a strong influence of dosing regimen and exposure time on dopamine 
release. This work suggests that, similar to rats, zebrafish might be an effective model of 
neurotransmitter release impairment in chemobrain.     
4.2 Methods 
4.2.1 Drugs 
Pharmaceutical grade carboplatin, 10 mg/mL (CD11650AA, Hospira, Lake Forest, IL, 
USA) and 0.9 % sterile saline (Nova-Tech Inc, Grand Island, NE, USA) solutions were used. 
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Dopamine was purchased from Sigma-Aldrich (St. Louis, MO, USA). Aqueous solutions were 
prepared with purified (18.2 MΩ) water. A modified artificial cerebrospinal fluid (aCSF) for 
zebrafish whole brain preparations consisted of 131 mM NaCl, 2mM KCl, 1.25 mM KH2PO4, 20 
mM NaHCO3, 2mM MgSO4, 10 mM glucose, 2.5 mM CaCl2·H2O, and 10mM HEPES, and the 
pH was adjusted to 7.4.  
4.2.2 Brain preparation 
All animal procedures were approved by the University of Kansas Institutional Animal 
Care and Use Committee. Wild-type adult zebrafish, originally purchased from 
AquariumFish.net, were housed 20 fish per 2L tank in the University of Kansas Molecular 
Probes Core (KU-MPC). Zebrafish were maintained on a light dark cycle with a 16 hour light 
phase and 8 hour dark phase. The temperature of the recirculating water system was maintained 
at 26 ̊C.   
Wholes brains were harvested as previously described17. Briefly, for a given experiment, 
a zebrafish was euthanized by hypothermic shock and decapitated using a 0.009” single edge 
razor blade (VWR Corporates, Radnor, PA, USA). The head was transferred to a prepared 
dissection pad made of 2% agarose (BioReagent graded agarose, Sigma-Aldrich, St. Louis, MO, 
USA) in a 100mm x 15mm petri dish (ThermoFisher Scientific, Waltham, MA, USA).  The petri 
dish was filled with oxygenated (95% O2/5% CO2) ice-cold modified artificial cerebral spinal 
fluid. The head was then immobilized by pinning it to the agar with a syringe needle. The skull 
of the zebrafish was carefully removed using forceps, and the brain was removed with a pulled 
capillary and transferred to the recording chamber, which was perfused with oxygenated-




4.2.3 Chemotherapy treatment 
For chemotherapy exposure through the water environment, fish were housed in 1 L of 
water to which pharmaceutical grade carboplatin in 0.9% saline (10 mg/mL) was added so that 
the final concentration of carboplatin was 100 µM. Control fish were housed in 1 L of water 
treated with an equal volume of 0.9% sterile biological saline. The fish were exposed 
continuously for 1, 4 or 7 days. Fresh solutions were made every 48 hours. 
The oral treatment procedure consisted of soaking 1 g of thawed, strained brine shrimp 
(San Francisco Bay Brand INC, Newark, CA, USA) for 30 minutes in carboplatin or saline to 
give the food a drug concentration of 20 mg drug/g of shrimp. A total weight 0.25 g of this 
shrimp was then added to the habitat water for a 3-minute period, allowing the fish to feed prior 
to being removed to clean habitat water. This treatment was carried out for 1, 4 or 7 days, after 
which the fish were sacrificed and analyzed.   
4.2.4 Electrochemistry 
Cylindrical carbon fiber microelectrodes were fabricated as previously described20. 
Briefly, a 7 µm diameter carbon fiber (Goodfellow Cambridge LTD, Huntingdon, UK) was 
aspirated into glass capillary tubes (1.2 mm D.D and 0.68 mm I.D, 4 in long; A-M System Inc, 
Carlsborg, WA, USA).  Loaded capillaries were then pulled using a PE-22 heated coil puller 
(Narishige Int. USA, East Meadow, NY, USA).  Pulled carbon fibers were trimmed to a length 
of 50 to 70 µm from the pulled glass tip. To seal the carbon fiber, electrodes were dipped into 
epoxy resin (EPON resin 815C and EPIKURE 3234 curing agent, miller-Stephenson, Danbury, 
CT, USA) and cured at 100 ̊C for 1 hour.  
Electrochemical measurements were collected and analyzed using an electrochemical 
workstation consisting of a Dagan Chem-Clamp potentiostat (Dagan, Minneapolis, MN, USA), 
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modified to allow gain settings down to 200 nA/V, a personal computer with TarHeel CV 
software (provided by R.M. Wightman, University of North Carolina, Chapel Hill, NC, USA), a 
breakout box, and two National Instruments computer interface cards, PCI 6052 and PCI 6711 
(National Instruments, Austin, TX, USA). 
During a typical recording session, the brain was allowed to equilibrate in the perfusion 
chamber for a period of one hour. A carbon-fiber microelectrode and two stimulating electrodes 
(A-M System Inc, Carlsberg, WA, USA) were micromanipulated into a whole zebrafish brain as 
previously discussed17. The carbon-fiber microelectrode was positioned 50 – 100 µm laterally 
from the medial olfactory tract (MOT) and inserted about 280 – 300 µm deep. The stimulating 
electrodes were placed at the center of ventral telencephalon and inserted about 100 µm into the 
brain so that the carbon-fiber microelectrode was positioned between stimulating electrodes. 
 To evoke dopamine release, a stimulation train of 35 electrical pulses (350 µA 
stimulating current, 4 ms of total duration, frequency of 60 Hz) was applied. Evoked dopamine 
release was measured using a triangular waveform of – 0.4 V to + 1.3 V to – 0.4 V at a scan rate 
of 400 V/s applied at a 10 Hz frequency. After stimulation and dopamine detection, the brain was 
allowed a 10 minute resting period before the next stimulation event was applied. Evoked 
dopamine released was measured from either treated fish brain or control fish brain for 1 hour. 
Electrodes were pre-calibrated and post-calibrated against standard dopamine solutions. The 
average of the pre- and post-calibration was used to convert measured current in the brain to 
dopamine concentration.  
4.2.5 Atomic Absorption Spectroscopy 
 Procedures based on those previously described were used.21 Briefly, a calibration curve 
was prepared by making solutions of carboplatin in water. The samples were analyzed using a 
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flameless method. A 10 µL sample was injected into a graphite furnace (Analytical West, 
Corona Ca, USA) and a heating regime of a 30 s at 125 ⁰C, a 20 s ramp to 1500 ⁰C, 30 s held at 
1500 ⁰C followed by 8 s at 2700 ⁰C was run. Data was collected using a hollow cathode lamp 
specific for Pt (Phrotron LTD, Victoria, Australia) measuring at 265.95 nm.  
4.2.6 Preparation of brain homogenates 
 Brains were collected after treatment with carboplatin (whole brains for the zebrafish and 
hemispheres for the rat brains) and frozen on dry ice. The brains were then stored at -80 ⁰C until 
they were analyzed. Homogenates were prepared by mixing the brain tissue with water at a ratio 
of 1 gram of wet tissue weight with 1 mL of water. This mixture was homogenized using a 
dounce homogenizer. The homogenized mixture was then centrifuged for 15 minutes and the 
supernatants were used for analysis.  
4.2.7 Data analysis and statistics 
 All numerical values were represented as mean ± standard error of the mean (SEM). For 
all analyses, n is equal to the number of zebrafish brains used unless otherwise noted. GraphPad 
Prism 6 (GraphPad Software Inc, La Jolla, CA, USA) was used to conduct statistical calculations 
and to present data. The modelling was achieved by analyzing the raw data to determine the point 
of maximum dopamine signal after stim and the point where that signal has decayed by 80%. This 
decay curve is then fit with the 1st order exponential decay equation At = Amax e
-kt. Amax is held 
constant at the experimentally determined value and k, the 1st order rate constant, is allowed to 
float. The accuracy of the fit is determined by using a Pearson coefficient with a cut off of R > 0.8 
being used. Once this k is determined the half-life of the decay is then calculated using the equation 
t1/2 = 0.6932/k. All data analysis and curve fitting was done using GraphPad Prism 6 (GraphPad 
Software Inc, La Jolla, CA, USA) 
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4.3 Results and Discussion 
 
Fig. 1 (A) Shows representative data for the control group and 7 days after 100 µM carboplatin 
treatment. The cyclic voltammagrams in both cases indicate that the neurotransmitter measured 
is dopamine. (B) Pooled dopamine concentration data for water treatment with 100 µM, there is 
a significant drug effect observed (p < 0.05 two-way ANOVA n = 5 brains) there is also a 
significant difference in release observed between the control and 7 day treatment groups 
(Sidak’s test * p, 0.05 n = 5 brains). 
 
4.3.1 Carboplatin water treatment.  
 Recently, our group showed that, in rats, the chemotherapeutic agent carboplatin caused a 
marked attenuation of dopamine release coupled with behavioral changes related to cognitive 
decline8. With these results in mind, we repeated the drug treatment and neurochemical 
measurements in zebrafish. In the initial experiments, zebrafish were treated through direct 
addition of either 100 µM carboplatin or an equal volume of biological saline into their habitat 
water and neurochemical measurements were taken from ex vivo whole brain preparations either 
1, 4 , or 7 days after continuous treatment. As shown in Figures 1A and B, release changed 
significantly until after 7 days of continuous treatment.  
Data from multiple fish were analyzed and a significant decrease in dopamine release 
was found after 7 days of treatment (two-way ANOVA, overall drug effect, p <0.05; Sidak’s 
multiple comparison test: 1-day 0.60 ± 0.14 µM control, 0.35 ± 0.09 µM treated, p = 0.017; 4-
day 0.41 ± 0.07 µM control, 0.29 ± 0.09 µM treated, p = 0.70; 7-day 0.63 ± 0.06 µM control, 
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0.27 ± 0.04 µM treated, p < 0.05, n = 5 brains). This decrease is consistent with previously 
published results in which rats were treated with carboplatin over the course of four weeks and 
dopamine release was measured in brain slices8.    
 
Fig. 2. (A) Representative data showing that there seems to be an attenuation in dopamine 
release after 7 days off food treatment. The cyclic voltammogram of the compound measured 
provides evidence that it is dopamine. (B) The pooled data shows a significant drug effect over 
the 7 days (two-way ANOVA p < 0.0001) as well as a significant decrease in the dopamine 
release after only 1 day that continues to be present at 4 and 7 days as well. (Sidak’s test * p 
<0.05, ** P< 0.01) 
 
4.3.2 Carboplatin food treatment.  
 Although treatment through the water habitat resulted in an overall drug effect and a 
measurable decrease in dopamine release by day 7, we sought to determine a treatment method 
that would yield more robust results. While it has been shown that fish gills can accumulate 
unwanted metals in contaminated water, food contamination has been found in laboratory 
experiments to be the more important pathway for the delivery of  molecules22,23; therefore, we 
administered the drug through their food. This was done for two reasons: 1) treatment through 
food is convenient and 2) carboplatin is known to cross the intestines in rodent models24. During 
this treatment, fish were fed brine shrimp with a concentration of 20 mg carboplatin/gram of 
drug once per day for 1, 4, or 7 days after which dopamine measurements were made from whole 
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zebrafish brain ex vivo. As shown in Figure 2 the representative data reveal a significant 
attenuation in the dopamine release after just one day of food treatment. This attenuation appears 
to remain constant even after further treatments. Analysis of multiple fish show a dose dependent 
change in dopamine release (Two-way ANOVA, overall drug effect, p < 0.0001; Sidak’s 
multiple comparison test: 1-day 0.47 + 0.07 µM control, 0.21 + 0.05 µM, treated p <0.05; 4-day 
0.53 + 0.065 µM control, 0.23 + 0.045 µM treated, p< 0.01; 7-day 0.52 + 0.094 µM control, 0.15 
+ 0.037 µM treated, p<0.01) that was significant compared to the control.  
These phenomena suggests that the effect of carboplatin on dopamine release in zebrafish 
is similar to that of results in rodent animal models. However, when the chemotherapy drug was 
delivered orally, chemotherapy treatment was more efficient than when the drug was delivered 
by treating habitat water. This observed difference in release may be related to the amount of 
intact drug that reaches the animal. It is not clear how much carboplatin can cross the skin and 
enter the blood stream. As such, it is likely that the water-treated fish are receiving less than a 
100 µM dose. During food treatment, since the fish are ingesting the drug instead of absorbing it 
through the skin, and it is known that carboplatin can cross the small intestine of rats24, they are 
more likely to receive the entire intended dose leading to the observed increase in attenuation. 
This theory is supported by the fact that in the water-treated fish the significant changes were not 
observed until after day 7, whereas, in the shrimp-treated fish the effect was immediate (Figures 
1 and 2).  
4.3.3 Atomic absorption spectroscopy  
 Our data have clearly shown that there is a dose- and treatment pathway-dependent 
attenuation of dopamine release in zebrafish. Our next concern was to determine where the drug 
was accumulating during treatment. There is a debate in the literature about whether platinum-
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based drugs can cross the blood brain barrier effectively without the aid of drugs that disrupt the 
blood brain barrier25-27. Thus, we sought to determine if the drug was crossing the blood brain 
barrier in zebrafish and, if it could, how much accumulated in the brain. In order to do this, we 
used flameless atomic absorption spectroscopy to measure the platinum in zebrafish whole 
brains. 
 
Figure 3: (A) Calibration curve for carboplatin in water measured by flameless atomic 
absorption spectroscopy. There is a linear relationship between concentration and response with 
significant positive slope (p<0.0001) and good correlation R2 = 0.99. (B) Amount of platinum 
measured in rate brain hemispheres, there was no significant difference between the amount 
measured in saline vs carboplatin treated (n = 4 brains).  
  
 As shown in Figure 3 platinum was detectable in calibration samples making a curve with 
good linearity and a limit of detection of 20 ng/mL. When rat brain hemispheres were analyzed 
we found that, while there were observable peaks, these peaks were found in both the saline and 
treated samples.  This conclusion is based on the finding that when the data are pooled the 
concentration measured is the same for both treatments groups (saline 0.040 + 0.0001 
µg/hemisphere; treated 0.039 + 0.0003 µg/hemisphere, t-test, p = 0.44, n = 4 brains). Thus, the 
observed peaks likely arise from organic contaminants, suggesting that this method did not detect 




Figure 4 (A). Representative data for 5-FU water treatment after 7 days. The signal has not 
changed significantly and the CV continues to look like that of dopamine. (B) The pooled data 
shows no significant drug effect throughout the treatment (two way ANOVA p = 0.98 n= 5 
brains) 
 
4.3.4 5-fluorouracil water treatment.  
 Once we had established that carboplatin seemed to have a similar effect in zebrafish as it 
did in rats, we sought to extend our study to a second chemotherapeutic agent in order to see if it 
was a generalized effect, or if it was limited to carboplatin. The drug chosen was the 
chemotherapeutic agent 5-fluorouracil (5-FU), a derivative of uracil that can disrupt both protein 
formation as well as the synthesis of thymine. 
 For the initial water treatment, a regime was followed that matched the one used for 
carboplatin: 1, 4, or 7 days of constant exposure to 100 µM 5-FU followed by neurochemical 
measurements from whole brain preparations ex vivo using fast scan cyclic voltammetry. As can 
be seen from the representative data in Figure 4, panel A, dopamine is present; however, there is 
no significant change in dopamine release after 7 days. This observation is born out when the 
data is pooled with no observed drug effect (no significant drug effect, two way ANOVA p = 
0.98, Sidak’s multiple comparison test; 1-day 0.60 + 0.14 µM control, 0.40 + 0.10 µM treated p 
= 0.51; 4-day 0.41 + 0.072 µM control, 0.565 + 0.12 µM treated p = 0.70; 7-day 0.63 + 0.064 
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µM control 0.68 + 0.18 µM treated p = 0.978 n = 5 brains). Unlike carboplatin treatment, there 
was no significant effect observed after 7 days of 5-FU treatment. It is possible this lack of effect 
was because the animal’s gills are more effective at filtering 5-FU then carboplatin. In any case 
based on our data, 5-FU does not cause a significant change in the release of dopamine after 
water treatment. 
 
Figure 5 (A). Representative data for 5-FU treatment after 7 days. The signal has clearly been 
significantly attenuated while the CV continues to look like dopamine’s. (B) The pooled data 
shows a significant drug effect throughout the treatment (two way ANOVA p < 0.001 n= 5 
brains) while there are significant attenuations in the dopamine release after 4 and 7 days ( * p 
<0.05, ** p < 0.01 Sidak’s multiple comparisons). 
 
4.3.5 5-fluorouracil food treatment  
 It was found that water treatment did not cause a significant change in observed release. 
It is also important to note that, while there is extensive evidence for metal accumulation through 
and in the gills for organics, it is known that some organics cannot cross the barrier.23 Also, it 
was found in LC50 experiments that 5-FU was nontoxic when it was administered through their 
habitat water28.  Since more efficient uptake was observed in carboplatin after food treatment we 
treated the fish with 5-FU through their food.   
 For these experiments, similar to the carboplatin experiments, brine shrimp with a 
concentration of 20 mg 5-FU/ g of shrimp were fed to the zebrafish for 3 minutes a day for either 
1, 4, or 7 days. The fish were then euthanized and neurochemical measurements were made form 
the whole brain ex vivo using fast scan cyclic voltammetry. As can be seen from the 
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representative data there appears to be a significant attenuation in release after 7 days (Figure 5 
A). Pooled data reveal a significant drug effect observed over the treatment regime, with 
statistically significant effects observed after 1 day of treatment (significant drug affect two way 
ANOVA p<0.001, Sidak’s multiple comparison test; 1-day 0.47 + 0.071 µM control, 0.263 + 
0.032 µM treated p = 0.073; 4-day 0.53 + 0.065 µM control, 0.243 + 0.034 µM treated p< 0.01; 
7-day 0.52 + 0.094 µM control, 0.29 + 0.040  µM treated p <0.05, n = 5 brains). These data 
agree well with what was observed in carboplatin treatment with both a significant drug effect as 
well as a significant attenuation after only 1 day. 
 Our data show that, for both carboplatin and 5-FU, the food treatment method displayed a 
quicker effect then the water data and in the case of 5-FU the only effect observed. This is an 
interesting phenomenon that may be occurring for several reasons. It is possible that the gills are 
able to efficiently filter out unwanted ions and small molecules such as Pt and 5-FU. This 
filtering could explain the much less pronounced effect for both of the compounds studied when 
they were delivered through the system water. It is also possible the effective concentration that 
the fish received from the food treatment was much higher than the concentration they received 
from the water treatment. It is difficult to estimate how much of the drug actually reached the 
fish because drug is allowed to diffuse away when the food hits the water. If the drug 
concentration is relatively higher for the food then the water treatment, it offers a possible 
explanation for the observed data. 
 Overall, we can make three conclusions with a high level of confidence from these data: 
(1) Chemotherapy treatment leads to an attenuation in dopamine release, similar to that observed 
in rats. (2) When administered through the habitat water, carboplatin has a greater effect on 
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dopamine release than 5-FU. (3) When administered by addition to food, carboplatin and 5-FU 
have approximately the same effect on release, decreasing it by ~ 60%. 
 
4.3.6 Kinetics of dopamine release 
 
Figure 6: Representative figure showing the raw experimental data with the simulated data from 
the modeled parameters overlaid. 
 
 In the preceding sections it has been shown that chemotherapeutic treatment attenuates 
dopamine release in zebrafish. With this result in mind we wanted to determine if uptake was 
also affected by modelling the 1st order rate constant of uptake (k). Understanding uptake is 
important because of the influence it has on the length of time dopamine is available to activate 
signaling pathways as well as the peak concentration of extracellular dopamine observed. Both 
of these phenomena can cause the effects discussed above.  
 The red line in Figure 6 represents a fit of the release data from the point where 
maximum signal is observed to the point were 80% of the signal has disappeared. This fit is 
achieved using Equation 1 
At = Amax e
-kt    Equation 1 
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In Equation 1, At is the signal at a given point of time, Amax is the maximum single observed, k is 
the 1st order rate constant for uptake and t is time29, 30. During the modelling, Amax was held at the 
experimentally determined value for the file of interest and k was allowed to float. The fit was 
determined to be valid if the modeled data had a Pearson coefficient greater than 0.8 when it was 
overlaid with the raw experimental data29, 30. The rate constant is a measure of the efficiency of 
the transporters as they uptake the released dopamine. This rate constant can also be used to 
calculate t1/2 for the uptake of dopamine.  The results of the modelling are shown in Figure 7. 
 
 
Figure 7. The averages of the 1st order rate constant (A and B top) and t1/2 (A and B bottom) in 
both water (A) and shrimp treated (B) zebrafish over the treatment time. There was no significant 




 It was determined that there was no significant difference between any of the treatment 
groups. Since this was the case all the control data was pooled and an average k was determined 
to be 0.2418s-1 + 0.018 with an n of  25 fish. This value is much larger than the reported numbers 
for both rats (0.012 to 0.027 s-1)30and fruit flies (0.062 + 0.004 s-1)29 and, therefore, indicates a 
fast reuptake in the zebrafish when compared to these species. We propose that this is because 
the model used does not account for diffusion as a factor and, as such, is over estimating the rate 
of uptake. While it is likely that the modelling is over estimating the rate value, it still points to 
uptake having no contribution to the attenuation in release observed. More work needs to be 
done to both calculate the Michaelis-Menten kinetic parameters for zebrafish as well as to take 
into account diffusion, which this current model assumes does not exist, in order to fully support 
this hypothesis.  
4.4 Conclusions 
 In this work we demonstrated that zebrafish are a candidate to be a model for 
chemobrain. We found that treatment pathway was significant to the observed attenuation of 
release. Food treatment was found to have a significant effect on release for both of the drugs 
studied after 1, 4 and 7 days of treatment. On the other hand, water treatment was only found to 
be effective when the fish were treated with carboplatin after 7 days. Furthermore, we showed 
that uptake was unchanged before and after treatment implying that it was not an explanation for 
the observed attenuation in release.  Finally, we demonstrated that Pt was not present in rat 
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Chapter 5 conclusions and future directions 
5.1 Conclusions 
 Our work in zebrafish has developed multiple interesting results. We have shown that it 
is possible to measure neurotransmitter release from intact whole brain tissue ex vivo, the first 
time that has been demonstrated. We examined the release in zebrafish and were able to compare 
it to the release in rodents and have shown that, though there were distinct difference between 
the shapes of the release curve in zebrafish when compared to rodents there were many 
similarities. Dopamine release is regulated both by uptake at the DAT, as demonstrated by the 
reuptake inhibitor experiments. The release events are also clearly regulated by D2 
autoreceptors, at least in the intact whole brains, as demonstrated by the sulpiride experiments.  
 We have also been able to show that the zebrafish’s neurochemistry seems to react in 
similar ways to the rodent’s neurochemistry upon introduction of chemotherapeutic agents. 
There is a marked decrease in dopamine release in both model organisms. Overall we feel that 
we have made a great amount of progress in showing that zebrafish are a valuable and viable 
model organism for neurochemistry that can complement other current model organisms like 
rodents and fruit flies.  
5.2 Future Directions 
 These are promising conclusions but there is still a lot of information that needs to be 
teased out to completely understand what is going on. The first main question that needs to be 
answered is what the identity of all of the analytes released during an experiment.. In order to try 
to determine the identity of the released species we tried to use principal component analysis1, 2as 
shown in Figure 1. While we had a limited amount of success with isolating signals by this 
method it was inconsistent. In the future it is possible that by optimizing the training sets, and 
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coating the electrodes with polymers such as nafion3 to limit possible extra signals we will be 
able to use PCA to successfully isolate signals in zebrafish. This would allow us to replicate 
what other groups have reported. 
 Determining how much of the signal comes from norepinephrine quantitatively can’t be 
done by using PCA because of the similarity of the CVs of dopamine and  norepinephrine. 
Another experimental method must be used to deconvulate these signals. It is possible that 
treatment with a drug that can either selectively stop norepinephrine synthesis or one that can 
selectively effect norepinephrine or dopamine release would allow us to deconvulate the signals. 
Stopping norepinephrine synthesis independently of dopamine synthesis is difficult, however, 







Figure 1: Example of PCA work in a zebrafish whole brain. (A) Shows the orginal color plot 
before the application of principal component analysis. (B) Shows the color plot after the 
analysis has been applied, as can be seen most of the signals not found where the stim artifact is 
have been accounted for. (C) Is the raw current vs time plot before the PCA analysis has been 
applied. (D) Is the dopamine component of the signal, the concentration of ~ 0.4 um was in good 
agreement with the average signal we would expect from a whole brain. (E) Is the DOPAC 
component and (F) is the ascorbate component. 
 
 Another important question is how large a natural occurring dopamine release event is. 
This is important to know because it will give us a gauge of how similar induced release events 
are to natural occurring events. This information would allow us to probe the hypothesis in 
chapter 3 that one of the reasons that we see such extreme overshoot in zebrafish is that much 
more dopamine is being released during an electrical stimulation event then would be observed 

















observed from an intact brain ex vivo and have seen none. We believe that in order to see events 
some sort of chemical stimulation, such as nicotine6, is needed. We think chemical stimulation is 
promising because we have observed unstimulated release events after treatment of the brain 
with deprenyl, a MAO inhibitor that has been found to be effective in zebrafish7. (Figure 3). We 
do not completely understand the underlying biochemical reasons for these observations at this 
point, however, we do believe that it is promising.  
 
 
Figure 3: After the initial electrical stimulation 3 transient like events were observed with CV 
similar to dopamine’s when the brain was treated with 10 uM deprenyl. 
 
 One of the distinct advantages of using whole brains is the fact that the neuronal circuitry 
should be intact. In order to take full advantage of this methods need to be developed to allow for 
remote stimulation of the neurons of interest. As was discussed in chapter 1 one of the main 
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dopamine systems in zebrafish extends from the diencephalon to the telencephalon. With this in 
mind we worked to stimulate in the diencephalon and measure the signal in the telencephalon, as 
seen in Figure 4. We were able to see clean dopamine release when this was done in 2 brains. 
While these results are promising they are inconsistent, without any disinguising features it is 
difficult to consistently place the stim electrodes in the diencephalon. We believe moving 
forward that some form of green fluorescence protein (GFP) labeling of neurons to allow for 
consistent placement of the electrodes is needed. GFP has been used in the past to study the 
development of and toxicity towards monoamine neurons8, 9 In order to use these technologies 
for our work staining needs to be specific for dopamine and we need to be able to image 
simultaneously with our electrochemical measurements.   
 
Figure 4 An example of remote stimulation, the stim electrode is placed in the diencephalon and 
the working electrode in the telencephalon. Clean release is observed with a clean CV.  
 Another promising avenue of work in the zebrafish is related to the mitigation of the 
neurochemical effects observed after treatment with the chemotherapeutic agent’s carboplatin 
and 5-FU. In order to examine this we treated the fish with the drug in their water at a 
concentration of 100 µM for two week then allowed the fish to recover for 2 weeks. The results 
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levels of saline fish (Carboplatin 0.419 + 0.197 µM n=3 brains, 5-FU 0.485 + 0.116 µM n=5 
brains, and Saline 1.39  + 0.335 µM n=4 brains). Also interestingly, unlike what was seen in 
chapter 4 after 1 week of treatment, 2 weeks of water treatment with 5-FU caused release to be 
significantly released, even with 2 weeks of recovery, (p<0.05 2 tailed t-test).  
 
Figure 5 Dopamine release after water treatment with 100 µM carboplatin or 5-FU. Both 5-FU 
(2-tailed t-test p<0.05) and carboplatin treatment (one-tailed t-test p<0.05) were significantly 
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